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Abstract  
Oesophageal squamous cell carcinoma presents a significant health burden in South Africa. It is 
one of the most common causes of cancer-related mortality of South African black males, as a 
result of its asymptomatic progression leading to late diagnosis and poor prognosis.  
The aim of this study was to identify membrane or membrane-associated proteins that are 
expressed at different levels in oesophageal tumour tissue when compared to normal tissue. The 
identification of such proteins would be an important step towards the development of better 
diagnostic and therapeutic strategies for this disease.  
Two proteomic approaches, were employed to identify differentially expressed proteins.  2D-
DIGE linked to MALDI-MS was used to identify altered protein levels in tumour tissue in 
comparison with normal tissue from OSCC patients. Collectively, 60 differentially expressed 
proteins were identified using this technique and a subset of proteins was selected for validation. 
The altered expression levels of gelsolin, HSP90B1 and annexin 2 were confirmed using 
immunohistochemical analysis, and the increased levels of annexin 2 were assessed as a 
potential marker for prognosis. The increased expression of several glycolytic enzymes was 
noted, including pyruvate kinase and GAPDH (confirmed by IHC). This presented a potential 
therapeutic target, and we proceeded to explore the glycolytic pathway as a target for 
therapeutic intervention in OSCC, using DCA. Unfortunately, the results achieved, reported that 
DCA is not an effective chemotherapeutic agent in OSCC. However, annexin 2, pending further 
investigation, could potentially be used as an early diagnostic marker. 
REQUA linked to ESI-QUAD-TOF MS was used in a cell culture system to compare a cultured 
oesophageal cancer cell line to a cultured normal oesophageal cell line. Higher levels of CD98 
hc were observed in the tumour cell line and IHC validation of this observation revealed that 
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increased CD98 hc levels occur as early as dysplasia, re-affirming CD98 as a molecular target 
for therapeutic intervention of OSCC. 
This study identified several regulated proteins that may be of use as markers or therapeutic 
targets to improve the diagnosis and prognosis of squamous cell carcinoma of the oesophagus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  iv 
Acknowledgements 
In no particular order, I would like to thank everybody who has contributed to me being able to 
complete this work.  
Dr Denver Hendricks played more than a supervisory role, and even though he writes it off as just 
being part of his job, he has supported me in more ways than one and I would never have completed 
this without him. 
Prof Parker is the reason I was fortunate enough to be part of this group and in addition to being my 
supervisor; he has been like a father figure. I will always be thankful for that! 
To Dr John Timms and all in the members in the lab in the UK, for allowing me to complete a big 
chunk of the work for this thesis at the Ludwig Institute for Cancer Research, UCL.  
To the lab members, present and past: Jacs, Nelusha, Pauline, Luke, Michelle, Kate, Bo, Wei, Dong 
Ping, Beverly, Kevin, Laja, Maurice and all the honours students. Thanks for always being there, 
whether it be just to chat or figure out a protocol. 
A special thanks to Dr Catherine Whibley and Adrianne Arendse, for support and encouragement in 
every way!  
To the lab members in other laboratories: Ray and Roshan, for allowing me to invade your space! To 
Ingrid Baumgarten and everyone in the NHLS Chemical Pathology lab at Red Cross. 
To the guys in Anatomical Pathology, Nafiesa, Heather, Dr Komala Pillay and Prof Dhiren Govender 
for teaching and guiding me in the world of IHC. 
To Prof Lutz Thilo, for being my unofficial other supervisor. Also, thanks to Dr Virna Leaner, for all the 
encouraging words of support. 
To my Lab family: Haji, Robbie, Lamize, Lee-ann, Graham and Aunty Sia. 
And to my family: My parents (Nadeema and Yousuf), for teaching me the importance of my studies 
and always encouraging me. For supporting me, even if it meant driving me to the lab at 2 am in the 
morning to complete experiments! To my brother and sister (Yousrie and Rashidah), for always being 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
  v 
the responsible ones and taking care of me! To Amirah and Shamsudeen, for providing me with the 
unconditional love only kids can give! 
To my Limbada parents and siblings: Fatima (thanks for proof-reading!), Ahmed, Aneesa, Faeez and 
Nailah, for support rendered during the final stages! 
To my friends, Ayesha, Nailah, Amaal, Yumna, Tasneem, Fayrous, Fuad, Yazeed and Faizel! 
Thanks for all your support and lending an ear! 
Last but obviously, never least…thanks to my husband…Rashid Limbada, without you, I would never 
have had the strength…thanks for being my rock, my strength…my life…you can have me back 
now…and now I can come to your cricket matches again! 
Finally, to my Creator, for everything we do in life, our faith is the one thing that never fails! 
 
 
 
 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  vi 
Table of Contents  
DECLARATION   I
ABSTRACT   II
ACKNOWLEDGEMENTS   IV
TABLE OF CONTENTS   VI
GLOSSARY   IX
1 OVERVIEW   1
1.1 Introduction   1
1.2 Pathology   1
1.3 Epidemiology   3
1.4 Aetiology   7
1.5 Challenges associated with oesophageal cancer   8
1.6 Approaches to challenges   9
1.7 Rationale for proteomic approach   12
1.8 Proteomic tools used for separation of proteins   13
1.9 Proteomic tools used for identification of proteins   18
1.10 Protein validation   19
1.11 Objectives of this study   20
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  vii 
2 2D-DIGE ANALYSIS OF TUMOUR TISSUE COMPARED TO NORMAL 
TISSUE   21
2.1 Introduction   21
2.2 Materials and methods   22
2.2.1 Tissue procurement   22
2.2.2 Preparation of samples   23
2.2.3 Protein labeling, separation and gel imaging   24
2.2.4 Image analysis, post-staining, spot picking and digestion   27
2.2.5 MALDI-TOF MS peptide mass fingerprinting   27
2.2.6 Immunohistochemistry (IHC)   28
2.2.7 Statistical evaluations and survival test   29
2.3 Results   30
2.3.1 Protein quantitation and labeling   30
2.3.2 2D-DIGE and MS protein expression profiling   31
2.3.3 IHC of selected targets   46
2.4 Discussion   51
3 ALTERED GLYCOPROTEIN PROFILE IN OSCC CELL LINE COMPARED 
TO AN IMMORTALIZED NORMAL OESOPHAGEAL CELL LINE   61
3.1 Introduction   61
3.2 Materials and methods   64
3.2.1 Propagation of cell lines   64
3.2.2 Labeling of plasma membrane glycoproteins, plasma membrane protein preparation 
and protein separation   65
3.2.3 Post-staining, gel anlysis, slice excision and digestion   70
3.2.4 ESI-QUAD-TOF MS and identification of proteins   72
3.2.5 Confirmation of protein expression by IHC   72
3.3 Results   74
3.3.1 Radioactive labeling of plasma membrane glycoproteins   74
3.3.2 Profile pattern of proteins showing altered levels of expression   76
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  viii 
3.3.3 Identification of proteins   80
3.3.4 Confirmation of protein expression by IHC   82
3.4 Discussion   86
4 DCA AS A POTENTIAL THERAPEUTIC DRUG IN OSCC   89
4.1 Introduction   89
4.2 Materials and Methods   92
4.2.1 Propagation of cell lines   92
4.2.2 Growth assays   93
4.2.3 Cell counting assays   94
4.2.4 Cell cycle analysis   94
4.2.5 Apoptosis assays (Caspase 3/7 activity)   94
4.2.6 Western Blot analysis (PARP cleavage)   95
4.2.7 Necrosis assay   95
4.2.8 PDH and lactate assays   96
4.2.9 Statistical evaluations   97
4.3 Results   97
4.3.1 Oesophageal cell lines display various levels of sensitivity to DCA treatment   98
4.3.2 Time-course of cell death   104
4.3.3 Effects of DCA treatment on the cell cycle profile of OSCC cell lines   105
4.3.4 Apoptosis or necrosis?   107
4.3.5 DCA does not affect PDH activity and lactate levels in OSCC cell lines   110
4.4 Discussion   111
5 CONCLUSION   116
APPENDIX A:   118
APPENDIX B:   128
REFERENCES   133
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  ix 
 
Glossary 
2D-DIGE - Two dimensional in Difference Gel Electrophoresis  
2DE - Two dimensional gel electrophoresis 
ADC - Adenocarcinoma of the oesophagus 
AML - Acute Myeloid Leukemia 
AQUA - Absolute Quantification of Abundance 
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Beta Gal - beta galactosidase 
CA125 - Cancer Antigen 125 
CANSA- Cancer Association of South Africa 
CBER - Center for Biologics Evaluation and Research 
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COFRADIC - Combined FRActional DIagonal Chromatography 
dATP - Deoxyadenosine triphosphate 
DCA - sodium dichloroacetic acid 
dCTP - deoxycytidine triphosphate 
dGTP - deoxyguanosine triphosphate 
DMEM - Dulbeccos modified Eagles medium 
DMF - N,N-dimethylformamide 
DNA - deoxyribonucleic acid 
dpm - disintegrations per minute 
DTT - 
dTTP - deoxythymidine triphosphate 
Dithiothreitol 
ECM - extracellular matrix 
EC50 – effective concentration at 50% 
EDTA - ethylenediaminetetraacetic acid 
EGFR-2 - Epidermal growth factor receptor 2 
ELISA - Enzyme-Linked ImmunoSorbent Assay 
ESI-QUAD-TOF-MS - electron spray ionisation linked to quadropole time of flight mass 
spectrometry 
FBS - fetal bovine serum 
FDA - Food and Drug administration 
FTICR - Fourier transform ion cyclotron resonance 
GAPDH - Glyceraldehyde-3-phosphate dehydrogenase 
Gleevec/imatinib mesylate 
GT - galactosyl transferase 
H2
HAT complex - Heteromeric Amino acid Transporter complex 
O - distilled water  
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Herceptin/trastuzumab 
HPLC - High Performance Liquid Chromatography  
HPV - Human Papilloma virus 
ICAT - Isotope-coded affinity tag  
IEF – iso electric focusing 
IHC - immunohistochemistry 
IPG – immobilized pH gradient 
ISO - International Organization for Standardization 
IT - Ion trap 
iTRAQ - isobaric tag for relative and absolute quantitation 
KCl - potassium chloride 
kVh – kilo volt hours 
KSFM - keratinocyte serum free media 
LAT-1 - L-amino acid transporter 
LC - liquid chromotography 
LCM - Laser capture microdissection 
m/z - mass to charge ratio 
MALDI-MS - Matrix-assisted laser desorption/ionization mass spectrometry 
MgCl2 
MS - mass spectrometry 
- magnesium chloride 
MS/MS/ Tandem MS/ MS
MTT - 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
2 
MuDPIT - multidimensional protein identification technology 
MW - molecular weight 
MWM - molecular weight marker 
Mylotarg/Gemtuzumab Ozogamicin 
NaF - sodium fluoride 
Na3VO4
NCI - National Cancer Institute 
 - sodium vanadate 
NHS - N-hydroxy succinimidyl  
OSCC - Oesophageal Squamous Cell Carcinoma 
O/N - overnight 
PARP - poly ADP ribose polymerase 
PBS - phosphate buffered saline 
PDH - pyruvate dehydrogenase 
PDK -  pyruvate dehydrogenase kinase 
PET - Positron emission tomography 
PI - propidium iodide 
PK2 - Pyruvate kinase M2 isozyme 
PMSF - phenylmethanesulphonylfluoride or phenylmethylsulphonyl fluoride  
PMT - photomultiplier tube  
PNS - post nuclear supernatant 
PSA - Prostate Specific Antigen 
QUAD - quadrupole 
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REQUA - Relative Quantification of glycosylated proteins 
RNA - ribonucleic acid 
ROS - reactive oxygen species 
RT - room temperature 
SA - South Africa 
SDS - sodium dodecyl sulphate  
SDS - PAGE - sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SELDI-MS - Surface-enhanced laser desorption ionization mass spectrometry 
SILAC - Stable Isotope Labeling with Amino acids in Cell culture 
TBS - tris buffered saline 
TBST - tris buffered saline plus Tween 
TOF - time of flight 
U - units 
UDP - Uridine diphosphate (diphospho) 
WB - western blot 
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1 Overview 
1.1 Introduction 
Squamous cell carcinoma of the oesophagus is a disease that disproportionately affects certain 
communities in developing countries (including South Africa) and is associated with a high mortality 
in these communities. Although various studies have provided a wealth of information describing 
possible mechanisms involved in the development and progression of cancer so that more effective 
treatment and diagnostic strategies can be developed, many questions remain. This, in part, reflects 
the complexity of the processes underlying tumourigenesis, which include genetic predisposition, the 
tissue involved, specific agents involved, certain chemicals and various other environmental factors. 
This particular study seeks to identify and characterize some of the proteins that may be involved in 
oesophageal cancer, since this knowledge may contribute to the development of better diagnostic or 
therapeutic strategies for this disease. 
1.2 Pathology 
Oesophageal cancer is classified into two main pathological types based on location and morphology 
of the tumour. Adenocarcinoma (ADC) occurs in the lower third of the oesophagus including the 
gastro-oesophageal junction (Fig. 1.1). The second type, oesophageal squamous cell carcinoma 
(OSCC) occurs in the upper two thirds of the oesophagus (Fig. 1.1). ADC develops in the distal part 
of the oesophageal epithelium primarily comprising columnar or cuboidal cells (in a glandular 
epithelium), whereas OSCC arises from stratified squamous epithelia, located more proximally in the 
oesophagus (Fig. 1.1). There are other important differences between these two cancers. ADC 
usually occurs in developed countries and is associated with obesity and gastro-oesophageal reflux. 
The observation that gastro-oesophageal reflux predisposes subjects to the development of ADC 
facilitates the identification of subjects that are at risk for developing ADC and can thus be used as 
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part of an early diagnosis program. OSCC usually occurs in developing countries and is a result of a 
different set of aetiological factors in comparison to ADC. Adequate/effective markers for early 
identification of OSCC have yet to be developed. Consequently, the early diagnosis of OSCC is not 
feasible and is generally associated with a high mortality rate, primarily a result of the late clinical 
presentation of the disease. 
 
 
 
 
 
Figure 1.1: Schematic diagram of oesophagus: Upper two thirds of the oesophagus comprises of 
squamous epithelia and the lower third is made up of cuboidal and columnar epithelia. (Images 
adapted from (1,2) 
The development of OSCC can be distinguished by five stages. Stage 0 is characterized by the 
presence of intra-epilthelial neoplasia (dysplasia and carcinoma in situ) (Fig. 1.2). Stage 1 is typified 
by the invasion of the tumour into the submucosal layer. Stage 2 can be divided into two categories, 
where Stage 2A refers to a tumour that has infiltrated the muscle layer of the oesophagus and Stage 
2B describes a tumour that has invaded all layers of the oesophagus as well as the lymph nodes. 
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Figure 1.2: Schematic diagram depicting the progression of oesophageal cancer. Stage 0 – intra-
epithelial neoplasia; Stage 1 – tumour invasion of the sub-mucosa; Stage 2 – tumour invasion of the 
muscle layers and lymph nodes; Stages 3 and 4 – tumour metastasis (image reproduced from (3). 
Stages 3 and 4 are usually associated with metastasis. Stage 3 tumours have metastasized to 
proximal tissues and lymph nodes and stage 4 tumours have metastasized to distal organs and 
lymph nodes (4).  Most OSCC patients present with symptoms at stages 2 to 4, which are 
associated with poor prognosis.  This late presentation of the disease contributes to the poor survival 
rate of patients diagnosed with OSCC. 
1.3 Epidemiology 
OSCC ranks as the eighth most common cancer in the world, affecting more males than females 
(Fig. 1.3) (5). It predominantly occurs in developing countries with areas of particularly high 
incidence localized to the Linxian District in China, parts of Iraq and Iran as well as parts of South 
America and certain regions in Africa (Fig. 1.4) (6-9). 
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Figure 1.3: Estimated ranking of most common cancers by number of cases (for all ages) in the 
world for the year 2002, where males are shown on the left and females are on the right (reproduced 
from Globocan, IARC, 2002) (9) 
 
 
 
 
 
 
 
 
 
Figure 1.4: World map depicting estimated age standardized incidence rates per 100 000 for 
oesophageal cancer in (a) males and (b) females for the year 2002 (reproduced from Globocan, 
IARC, 2002) (9) 
 
In South Africa (SA), OSCC presents a significant health burden, with an age-standardized incidence 
of 11.3 per 100,000 for males and 5.5 per 100,000 for females (5).  The incidence of OSCC ranks 
third in the South African male population, preceded only by prostate and lung cancer (5). In South 
African females, the incidence of OSCC ranks as the fourth most common cancer with breast 
cancer, cervical cancer and colorectal cancer as the three leading cancers (5). Although it has been 
reported that the risk for developing OSCC has decreased in SA between 1998 and 1999 (5), these 
reports are yet to be reproduced. The South African National Burden of Disease studies estimates 
that 1.1% of total deaths in SA in the year 2000 was due to OSCC (Table 1.1) (5,10). The data in 
Table 1.1 suggests that OSCC is one of the most common causes of cancer-related deaths in SA, 
emphasizing the high incidence, poor survival rates and public health burden of this disease. 
a b
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Table 1.1: Ranking causes of death in SA in the year 2000, according to the National Burden of 
Disease reports (reproduced from (10))  
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Deaths (Persons) 
Rank Cause Total % 
1 HIV/AIDS 132 990 25.5 
2 Ischaemic heart disease 34 402 6.6 
3 Stroke 33 866 6.5 
4 Tubercolosis 28 907 5.5 
5 Interpersonal violence 27 563 5.3 
6 Lower respiratory infections 22 910 4.4 
7 Hypertensive disease 16 648 3.2 
8 Diarrhoreal diseases 16 006 3.1 
9 Road traffic accidents 15 993 3.1 
10 Diabetes Mellitus 13 546 2.6 
11 Chronic obstructive pulmonary disease 12 768 2.5 
12 Low birth weight 11 597 2.2 
13 Asthma 7 006 1.3 
14 Trachea/bronchi/lung cancer 6 885 1.3 
15 Nephritus/nephrosis 6 760 1.3 
16 Septicaemia 6 234 1.2 
17 Oesophageal cancer 5 579 1.1 
18 Protein/energy malnutrition 5 499 1.1 
19 Suicide 5 461 1.0 
20 Cirrhosis of liver 5 442 1.0  
 Top twenty %  79.8 
 All causes 521 082  
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1.4 Aetiology 
A variety of environmental factors have been associated with the development of OSCC in various 
parts of the world (11). In the South African population, excessive smoking and alcohol consumption 
are the leading factors associated with the development of OSCC (5,6,12), although, other factors 
have also been associated with the development of this disease. These include, HPV infection status, 
the use of emetics, consumption of fumonisin contaminated maize, home-brewed beers made from 
fusarium-infected maize and nutritional deficiencies (specifically lack of Vitamin A and C, riboflavin, 
folic acid and magnesium) (5,11-16).  Interestingly, the diets of those in the high incidence areas in 
SA primarily consists of maize, which contains low levels of niacin, riboflavin, vitamin C, zinc, 
calcium, folic acid and magnesium (5,17). 
Although a number of environmental factors have been implicated in the development of OSCC, 
worldwide, a few common themes have emerged. These include chronic exposure to smoke, alcohol 
and other factors, such as drinking hot beverages (5,11,18) (observed in South America and Iran) 
and the use of emetics in traditional health practices in SA (19), that lead to chronic irritation of the 
oesophagus. The link between chronic inflammatory processes and cancer has previously been 
summarized in a review by Coussens et al (20).  
Even though various environmental factors have been linked to the development of OSCC, the 
molecular events leading to the development of the disease are, as yet, poorly understood. 
Investigating the molecular mechanisms involved in the development of OSCC could lead to the 
identification of molecular events associated with the development of the disease, or identify 
genes/proteins that maintain tumour progression. Tumourigenesis is underpinned by the 
dysreglated expression and function of a wide range of genes and proteins that lead to 
uncontrolled cell growth. Cancer biologists have in recent years gained considerable insight into 
some of the molecular mechanisms that are responsible for the development of some cancers, 
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facilitating the design of better diagnostic tools allowing the identification of at risk individuals 
and also developing cancer therapeutic agents that specifically target irregular cellular processes 
(21). Although the review by Hanahan and Weinberg (22) is slightly dated, it still provides a 
particularly clear perspective of the bewildering variety of molecular alterations associated with 
the development of cancer. It also catergorizes these alterations into distinct classes (or 
hallmarks), which include self-sufficiency in growth signals, evasion of apoptosis as well as 
tissue invasion and metastasis, among others. A recent review by Ullah and Aatif (23) further 
outlines how the development of cancer can be targeted for cancer therapeutic intervention. To 
illustrate this point, two different cancers (breast cancer or colon cancer) may display alterations 
in different genes, (Her2/Neu or Ras) with each alteration resulting in self-sufficiency in growth 
signals in that specific cancer (22). This sort of information has effectively been used to develop 
a therapeutic agent (Herceptin) for the treatment of those breast cancer patients with elevated 
levels of Her2/Neu (24-26). 
By using a variety of new techniques, cancer biologists are constantly identifying new targets for 
therapeutic purposes and simultaneously contributing to the molecular understanding of the 
neoplastic process. Approaches used to explore these molecular alterations include the use of 
either genomic and/or proteomic techniques. 
1.5 Challenges associated with oesophageal cancer 
Considering that most patients with OSCC are diagnosed at a late stage, with a 5-year survival rate 
of 14% (6,11), current treatments are primarily aimed at extending the life expectancy and quality of 
life of patients (27). In patients with advanced stage OSCC, palliative treatment as opposed to 
therapeutic intervention is provided (4). Since the present treatment options (which include 
radiotherapy, surgery and chemotherapy) are not effective in treating late stage OSCC, efforts to 
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improve the low survival rate associated with OSCC should include either earlier diagnosis or 
developing better treatment options.   
 
1.6 Approaches to challenges 
Developing procedures for the early diagnosis of OSCC (when the disease is more manageable) 
and/or designing better or more specific drugs, could significantly improve the prognosis for OSCC 
patients. The identification of biomolecular markers (biomarkers) in the early stages of OSCC would 
facilitate early diagnosis, thereby improving the prognosis for OSCC patients.  
The identification and development of biomarkers (for the early detection of cancer) hold considerable 
promise for OSCC patients, especially considering that some biomarkers are already used clinically 
for other cancers. Current biomarkers used for early detection in a clinical setting include, CA125 for 
ovarian cancer (28-30) and PSA (prostate specific antigen) for prostate cancer (31-33).  Despite the 
high rate of false positives, CA125 serves as a good prognostic indicator for ovarian cancer. CA125 
has been clinically useful in determining disease re-occurrence as well as serving as an indicator for 
post-operative/follow-up surgery (34).  PSA is effective in the diagnosis of prostate cancer, but has no 
prognostic significance (31). PSA has improved the diagnosis of prostate cancer dramatically since 
its discovery and has paradoxically led to an apparent increase in the incidence of prostate cancer 
observed, due to its widespread use as a screening tool for prostate cancer (35,36).  
Current thinking suggests that the sensitivity and specificity of a diagnostic tool, based on 
biomarkers, would improve if multiple biomarkers were incorporated in the assay (37). There is 
clearly a need to identify and characterize potential biomarkers for the early detection of OSCC. 
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Although early diagnosis is often associated with a better prognosis (38), current treatment options 
are either very invasive (surgery) or associated with a number of side-effects (chemo-and 
radiotherapy). The side-effects of chemo- and radiotherapy reflect the method of action of these 
treatments, i.e. that they often target all rapidly dividing cells. Unfortunately, chemotherapeutic 
approaches also affect normal rapidly dividing cells, such as those found in hair follicles, bone 
marrow, and the lining of the gastrointestinal tract. Side-effects experienced during cancer 
chemotherapy therefore usually include, alopecia (hair loss), myelo-suppression (reduction in activity 
of the bone marrow), and nausea (39-42).   Therefore, in addition to the requirement for the 
development of a robust panel of specific and sensitive biomarkers for the early detection of OSCC, 
there is also a need to develop therapeutic agents that selectively target OSCC cells more effectively 
than current treatment regimes. 
In recent years, scientists have been able to identify some of the molecular changes leading to 
cancer development, enabling them to develop treatments that specifically target abnormal cells. 
These treatments target only tumour cells and not normal cells and are known as targeted therapies. 
Various research groups, in collaboration with pharmaceutical companies have (and still are) 
investing an immense amount of time and money in identifying molecular targets for the purpose of 
targeted therapy (Genentech Inc, AstraZeneca Int. and Wyeth Pharmaceuticals). Some of the major 
categories of this new generation of cancer chemotherapeutic agents are monoclonal antibody 
therapy, small molecule inhibitors and apoptosis inducing drugs (43).  
In breast cancer, increased levels of human epidermal growth factor receptor 2 (EGFR-2 or Her-
2/Neu) in breast cancer cells compared to normal cells have been exploited through the use of a 
monoclonal antibody that blocks homodimerization of the receptor by binding to its extracellular 
domain and subsequently flags the cell for destruction via the immune system (25). This monoclonal 
antibody therapy, Herceptin ® (made by Genentech Inc.) is already being used in a clinical setting. 
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Although, this therapy is only available to those patients displaying increased levels of EGFR-2 in 
their tumours (about 25% of breast cancer patients) (25), results from clinical trials indicate the risk of 
breast cancer recurrence is decreased by 52% when Herceptin ® is used in conjunction with 
standard chemotherapeutic agents, compared to the use of standard chemotherapeutic agents on 
their own (26).  
An alternative approach to monoclonal antibody therapy is demonstrated by Gemtuzumab 
Ozogamicin (Mylotarg® made by Wyeth Pharmaceuticals), which is a calicheamicin-conjugate 
linked to an antibody to CD33 that selectively targets leukemia cells (44). This selectivity is based on 
the observation that acute myeloid leukemia (AML) cells have increased levels of CD33 compared to 
normal hematopoietic stem cells in more than 80% of patients with AML (44-46). Data reflecting its 
effectivity in decreasing risk of mortality as well as its prognostic significance is yet to be released.  
The second type of targeted therapy includes the use of small molecule inhibitors. These have been 
designed to target surface proteins involved in cell signaling for example. Iressa ® (ZD1839 or 
gefitinib - AstaZeneca Int.) targets epidermal growth factor receptor (EGFR), which is elevated in 
many cancers (47-49). Although both Iressa ® and Herceptin ® target EGFR, Iressa ® acts by  
competing for binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor 
autophosphorylation and resulting in inhibition of signal transduction  (50,51). Clinical trial results 
showed that treatment with Iressa ® alone failed to improve prognosis of patients (51,52).  
The third type of targeted therapy involves the use of apoptosis-inducing drugs. One of these 
therapies includes, Genasense ® (oblimersen - Genta Inc.), which inhibits the production of BCL–2, 
an anti-apoptotic signal promoting the survival of tumour cells. Some tumours express elevated levels 
of BCL-2, protecting these abnormal cells from apoptotic signals (53,54). By reducing BCL–2 levels 
in cells, Genasense ® increases the sensitivity of cancer cells to other conventional anticancer drugs. 
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Genasense ® is currently in clinical trials for the treatment of leukemia, non-Hodgkin’s lymphoma, 
and solid tumours (55-57). 
An underlying theme in recent drug development programmes that involve targeted therapy is the 
exploitation of proteins that are either overexpressed in cancer cells or that play critical roles in the 
maintenance of the cancer phenotype. The potential development of these novel therapies require the 
identification of protein targets like EGFR-2, CD33 or BCL-2 in those cancers that are characterized 
by poor prognosis, like OSCC. 
In OSCC, the identification of a surface protein displaying markedly elevated levels in tumour cells 
compared to normal in OSCC patients, would be a first step in the development of a targeted therapy 
approach. This study aims to address this issue by identifying and characterising altered surface 
protein levels in tumour cells compared to normal cells in OSCC using two proteomic approaches. 
1.7 Rationale for proteomic approach 
Current approaches to cancer therapeutics have in recent years been informed by novel findings in 
biomedical science, and our increased understanding of the molecular events occurring during the 
process of tumourigenesis. Methods have been developed that allow parallel examination of 
expression of genes or proteins (genomics and proteomics), enabling the determination of differential 
gene/protein expression. The differences in gene/protein expression between normal and cancer cells 
could facilitate the identification of molecules important in cancer development, which could 
conceivably serve as targets for the development of novel agents. 
Genomic methods for identifying potential therapeutic targets include differential gene profiling by 
subtractive hybridization, serial analysis of gene expression (SAGE), differential display reverse 
transcription polymerase chain reaction (DDRT-PCR) and micro-array technologies (58-60).  These 
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technologies have contributed to the identification of a number of diagnostic markers that are involved 
in cell signaling and are also potential targets for developing cancer therapeutics (60,61). 
Using SAGE, researchers identified mesothelin (a protein normally expressed on the surface of 
certain cell types) as an overexpressed protein in pancreatic tumour tissue compared to normal cells 
(62). Other cancers characterized by very high surface mesothelin expression include mesothelioma 
and ovarian carcinoma (63).  This protein has been identified as a target for cancer therapy and an 
immunotoxin to mesothelin, SS1(dsFv)-PE38 (SS1P), is in phase 1 clinical trials (Clinical trial 
identifier: NCT00024687).  
In recent years micro-array analysis have been used more often as the technology became more 
accessible and amenable to high throughput processing (60). Micro-array technology has led to the 
development of a 21-gene array to select appropriate treatments for a subset of breast cancer 
patients (64-67). This multi-gene array is currently used as a test to predict distant recurrence in ER-
positive (estrogen receptor positive) breast cancer patients. The cost of these tests are relatively high, 
but it has been suggested that the potential saving in selecting the correct treatment would outweigh 
this initial expense (68).  
The sequencing of the human genome has enabled a revolution in identifying genes that display 
altered expression in tumour compared to normal tissue. However, considering that less than 35 000 
genes code for more than 500 000 proteins, the human proteome  also provides a substantial amount 
of information that can be mined to identify differences in expression (69).  
1.8 Proteomic tools used for separation of proteins 
Methods used in quantitative proteomics rely on the fact that the same protein, obtained from 
different complex samples (e.g. tumour and cancer), would separate in a similar manner, thereby 
allowing comparative expression analysis. Sample complexity is an important factor to consider when 
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choosing a method of protein separation. The reduction of sample complexity can be achieved in a 
variety of ways. In plasma samples, highly abundant proteins (such as albumin and 
immunoglobulins) should be removed to focus on separating and identifying lower abundance 
proteins. In protein samples obtained from cultured cells, sample complexity can be reduced by 
fractionation methods that allow one to analyze proteins from various compartments within the cell 
(membrane, nucleus or cytoplasm). Sample complexity can also be reduced by isolating proteins on 
the basis of their post-translational modifications, such as glycosylation (as will be discussed later) or 
amino acid composition (targeting cysteine containing peptides).  
Laser Capture Micro-dissection (LCM) can also be used to isolate cells of interest and excludes 
contaminating proteins from surrounding tissue (70). Unfortunately, LCM is often not easily 
accessible and generally expensive and time-consuming. Essentially, reducing sample complexity 
would facilitate better protein separation. 
The primary aim of the separation step is to separate proteins by virtue of their size, charge or 
hydrophobicity or a combination of these. Protein separation can be achieved either by gel-free or 
gel-based methods (Fig. 1.5).  
Gel-free methods include methods such as MudPIT - Multidimensional Protein Identification 
Technology- (71), ICAT - Isotope-Coded Affinity Tags - (72), iTRAQ - Isobaric tags for relative and 
absolute quantitation - (73) and SILAC - Stable Isotope Labelling by Amino acids in Cell culture - 
(74,75).  The latter mentioned methods all involve differentially labelling samples either at cell/tissue, 
protein or peptide level, digesting the sample (where required), separation on the basis of its ionic 
status and subjected to MS.  Other gel-free methods include SELDI-MS (Surface Enhanced Laser 
Desorption Ionization Mass Spectrometry) and protein arrays. 
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Figure 1.5: Schematic diagram illustrating the basic workflow of a quantitative proteomic approach, 
which includes three main phases; separation, identification and validation. Separation techniques 
include either gel-free or gel based methods. Identification can be achieved using a combination of 
different ion sources, mass analyzers and detectors. Validation is considered a critical step in the 
workflow. 
Principally, all gel-free based separation methods allow the separation of peptides either by virtue of 
its size, charge or hydrophobicity. In the case of MudPIT, peptides are first separated by nature of 
their charge, using a strong cation exchange and followed by separation by nature of their 
hydrophobicity, using reverse phase chromatography. The latter is linked directly to an ion source 
and peptides are subjected to MS analysis. Both ICAT and iTRAQ involve labelling peptides with 
isotope-labelled reagents. In ICAT peptides are labelled at their cysteine residues, whereas iTRAQ 
involves labelling the N-terminus of peptides. Both ICAT and iTRAQ labelling methods occur after 
protein digestion, as opposed to SILAC, in which isotope labelling occurs in vivo. SILAC relies on the 
incorporation of amino acids with substituted stable isotopic nuclei (74).  
These methods have contributed to the rapid evolution of proteomic technologies. However, there are 
a few disadvantages associated with the use of these high-throughput methods that should be 
highlighted.  
Separation
Gel free             Gel based
LC 1D-PAGE
ICAT AQUA (stage2)
iTRAQ Gel C
SILAC         REQUA
COFRADIC 2D-PAGE
SELDI
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Protein arrays
Identification
Ion source:
1) MALDI
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Mass analyzers:
1) TOF + reflectron +delayed 
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1) Electron multiplier
2) Fourier transform
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Validation
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Although, MudPIT is a high throughput method that can be utilized for complex protein mixtures, it is 
not able to detect any modifications to proteins in complex mixtures. MudPIT also yields a substantial 
amount of MS data, however, special programmes and algorithms have been developed to cope with 
the immense amount of spectra produced from this method (76,77). 
Even ICAT is limited by the fact that it does not account for those proteins that have little or no 
cysteine residues. Furthermore, like MudPIT, ICAT does not facilitate the observation of changes in 
post-translational modifications.  
iTRAQ, on the other hand, is considered to be more sensitive than ICAT labelling, as more peptides 
per protein are identified resulting in better statistics (78).  Unfortunately, iTRAQ is very expensive in 
comparison to other methods. 
ICAT and iTRAQ use chemical labelling methods that require the two proteomes being analyzed to 
be purified and fractionated, separately.  The drawback is that the purification and fractionation steps, 
from the two separate proteomes, needs to be exactly the same in order to facilitate relative 
quantification. SILAC, however, is a metabolic labelling method that allows purification and 
fractionation of mixed populations allowing a more accurate quantification, as minimal errors could be 
introduced. SILAC displays a high degree of labelling, quantitation is simple and it is a relatively 
inexpensive method. The disadvantages of SILAC, however, include that one can only label cells in 
culture and that in some instances cells do no respond well to the media used during labelling (75). 
Various software packages have been developed to cope with the enormous amounts of information 
generated from these gel-free techniques. Despite the disadvantages associated with the above high-
throughput proteomic tools, they offer the opportunity to reveal a number of potential targets for 
cancer therapeutic intervention (69,79).  More recently, the drive towards proteomic based profiling of 
diseases has sparked an interest in clinical proteomics. A gel-free separation approach that recently 
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attracted attention is SELDI-MS (Surface-enhanced laser desorption/ionization linked to mass 
spectrometry) (80). This approach involves separating proteins using various chromatographic 
surfaces with different chemical characteristics (hydrophobic, cationic, anionic, metal presenting or 
hydrophilic). This high-throughput technology was earmarked as the technique to identify potential 
biomarkers of disease from serum, urine or other clinical samples, (80-82).  
Protein arrays are another example of a gel-free based method that would be ideal in a clinical setting 
as it can be likened to an ELISA assay. The overall concept is more like a micro-array. Protein arrays 
are both quantitative and qualitative and allow complex analyses in one operation. Protein arrays are 
very expensive and high risk. Furthermore, this technique also only allows for the identification of 
known proteins and is suitable for analyzing treatment effects over populations of samples, but is not 
well suited to assess individual patients (83,84). Proteomic techniques are rapidly advancing and 
other gel-free methods that are either novel or developed from current proteomic methods have 
entered the market (85-92). Generally, gel-free methods of separation mainly out-compete gel-based 
methods when a high-throughput technique is required.  
Gel-based methods of separation should not be discounted though, considering that various 
laboratories have generated valuable information using these methods (70,93,94).    
Gel-based methods of separation can be divided into 1-dimensional gel electrophoresis or 2-
dimensional gel electrophoresis. 1-dimensional gel electrophoresis allows the separation of proteins 
by virtue of its size. Although this approach is not popular, it is used in the first stage of AQUA (92), 
GelC (95) and REQUA (Relative quantification of glycosylated proteins) (96-98), which will be 
described in detail later.  
The most commonly utilized gel-based method is 2DE and conceptually involves the separation of 
protein mixtures by virtue of their charge and size (99). However, there are a number of problems 
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associated with this approach that include the poor detection of some proteins (mainly low 
abundance proteins, highly charged proteins and hydrophobic proteins),  imperfect separation, 
reproducibility and lack of automation (78).  
Recently an advance in 2DE technology, where protein samples are separately labelled with different 
fluorescent dyes, combined and separated on the same 2 dimensional gel was developed and 
termed 2D-DIGE (two-dimensional difference gel electrophoresis) (100). Although this method does 
not address the separation of low-abundant, highly charged or hydrophobic proteins, it does allow 
increased reproducibility and sensitivity to allow better quantification. Furthermore, the software and 
scanning methods allow automated detection of proteins of interest that are highlighted for 
identification. This approach was selected as one of the separation techniques used in this project. 
1.9 Proteomic tools used for identification of proteins 
The rapid advance in proteomic technologies has led to the development of various software 
packages and databases to facilitate the identification of proteins of interest. The proteomic tools 
used for the identification of proteins can be divided into the ion source, the mass analyzer and the 
detector (Fig. 1.5). The ion source can either be electron spray ionization (ESI) or the protein/peptide 
target can be immobilized on a matrix via matrix assisted laser desorption ionization (MALDI). 
Typically LC-based separation methods are directly linked to ESI in order to achieve a higher 
sensitivity. The disadvantage of ESI though is that once the sample has been sprayed/nebulized, a 
large volume is lost as a result of evaporation. Conversely, MALDI allows immobilization of the target 
protein/peptide, facilitating multiple ionizations of the same target.  
The resolution and added sensitivity of identification is nonetheless dependant on the mass analyzer. 
Mass analyzers are either based on the time of flight (TOF) that the ionized peptide takes to travel a 
set distance within a vacuum, or by trapping ions in an oscillating electrical field (Ion trap-IT) or by 
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filtering ions using 4 rods, which utilize a combined alternate and direct current, based on the 
ionization status (quadrupole). The resolution of the TOF mass analyzer can further be improved with 
the addition of a reflectron and delayed extraction of the ions. In addition, by having two mass 
analyzers in tandem, where the first would serve as a collision cell and the second would be the 
mass analyzer, one would increase the sensitivity level of identification. Tandem MS (aka MS/MS 
and MS2
These mass analyzers are in turn connected to a detector that amplifies and digitizes the signal. The 
most common type is the electron multiplier tubes, nevertheless, the more expensive, yet more 
sophisticated, is the Fourier transform ion cyclotron resonance detector (FTICR). The latter detector 
is based on, as the name suggests, Fourier transform technology. Briefly, it is a type of particle 
accelerator in which electrons are captured in orbits by an exceptionally strong magnetic field, whilst 
acceleration is facilitated by an applied voltage. This technology is currently utilized in only a handful 
of laboratories around the world. 
) facilitates the identification of a protein at an amino acid level. 
In spite of this, a recent technological advance yielded the Orbitrap. The Orbitrap is a much cheaper 
system that yields nearly the same efficacy as that of the FTICR. It generates an electrostatic field 
using one electrode within another that allows the ions to oscillate along the axis of the tubes. 
Similarly to FTICR, Orbitrap also utilizes Fourier transform technology to clarify individual frequencies 
that are related to the m/z (mass/ charge) ratio. 
Various combinations of each part of the mass spectrometer result in machines of varying speeds, 
sensitivities and resolutions in identifying proteins of interest. The combination of choice relies on 
availability of instruments. Regardless of the combination of choice used to identify the proteins, it is 
imperative to validate the expression level of the protein of interest using an alternative method.  
1.10 Protein validation 
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It is important to validate the information produced from the previous techniques before further work 
is carried out. The methods of validation most frequently used are western blot analysis and 
immunohistochemical analyses (of frozen tissue or archived paraffin blocks of tissue).  
Western blot (WB) involves confirming the expression levels of a protein of interest observed from the 
same protein sample used in the first stage of the proteomic approach.  Multiple samples can be 
analyzed using this approach, to determine reproducibility. This method has the advantage in that 
multiple proteins can quantitatively be analyzed in a simple and effective manner. However, western 
blot does also not allow one to visualize the sub-cellular localization of proteins.  
Immunohistochemistry (IHC) allows both quantitation and visualization of sub-cellular localization of 
the proteins of interest. This approach requires careful selection of antibodies to minimize non-
specific reactions and the assistance of pathologists to interpret the stained sections accurately. 
Identifying and validating altered levels of proteins in tumour compared to normal is the first step 
towards identifying potential diagnostic markers or targets for cancer therapeutic intervention. 
1.11 Objectives of this study 
Our laboratory has previously embarked on identifying genes that are differentially expressed in 
tumour tissue compared to normal tissue in oesophageal cancer, using differential display and micro-
array technology. A subset of genes identified are currently being further investigated as potential 
early biomarkers for oesophageal cancer (101).  
Genomics and proteomics complement one another and in this context, we developed this project to 
determine the proteomic profile of tumour tissue compared to normal tissue, from OSCC patients, 
with the primary focus on identifying potential therapeutic targets (given that most drug targets are 
proteins) (102). Furthermore, current therapeutic approaches do not effectively target tumour cells as 
opposed to normal cells in OSCC. This has created the demand to identify proteins on the surface of 
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the cell that displays increased levels in tumour cells compared to normal cells that could potentially 
serve as targets for cancer therapeutic intervention. 
In this study, we used a combination of proteomic approaches to address our objectives, which 
include: 
Objective 1 
To identify plasma membrane proteins that display altered levels in tumour cells compared to normal 
in OSCC using two different approaches. In the first approach, we intend on using proteins extracted 
from tumour and corresponding normal tissue. In the second approach, we intend on using proteins 
extracted from oesophageal cancer cell lines and an immortalized normal oesophageal cell line. 
Objective 2 
To validate the altered levels displayed by proteins’ of interest in OSCC by using a method that 
allows visualisation of the sub-cellular localisation of the proteins of interest. 
Objective 3 
To determine the value of altered protein levels as markers for OSCC or as targets for therapeutic 
intervention.  
2 2D-DIGE analysis of tumour tissue compared to normal tissue 
2.1 Introduction 
The most commonly utilised application in proteomics is two-dimensional gel electrophoresis (2DE), 
for separation of proteins, coupled with mass spectrometry (MS) for the identification of proteins. 
More recently, two-dimensional difference gel electrophoresis (2D-DIGE) has been applied for the 
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separation and accurate quantitation of protein for differential expression profiling of multiple 
biological samples. 2D-DIGE avoids the variation associated with conventional 2DE by pre-
electrophoretic covalent labelling of proteins with different fluorescent tags, allowing three different 
samples to be compared on a single gel (103).  This innovation substantially simplifies the 
comparison and analysis of paired samples (normal and tumour tissue for example), since the 
comparison takes place within the same gel. Furthermore, by using one of the tags to label an 
internal standard, spot matching across gels and accuracy of quantitation can be improved. 2D-DIGE 
has previously been used to identify proteins that are differentially expressed in tumour compared to 
normal cells in cancer of the breast (104), oesophagus (70,105), pancreas (106), colon (107) and 
liver (108), using whole cell protein lysates. 
The aim of this study was to identify differentially expressed proteins in the cell membrane and 
cytoplasmic fractions of tumour tissue compared to normal tissue from oesophageal cancer patients. 
 
 
 
 
 
 
2.2 Materials and methods 
2.2.1 Tissue procurement 
This study was approved by the Ethics Committee at the University of Cape Town (Reference: 
146/2004). Oesophageal tumour and adjacent normal tissue was obtained by informed consent from 
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44 oesophageal cancer patients who had undergone oesophageal biopsies at Groote Schuur and 
Tygerberg Hospitals in Cape Town, South Africa. Health personnel administered the consent forms 
and patient confidentiality was strictly maintained throughout. Tumour samples were only used for 
the study if greater than 90% of the tissue was identified as neoplastic by the attending pathologist.  
Normal oesophageal epithelium distant from the tumour biopsies were used after it had been 
determined that these samples were free of tumour tissue.  The tissue samples were frozen in liquid 
nitrogen and stored at -70°C until further use. 
2.2.2 Preparation of samples 
Tissue from oesophageal tumour biopsies were pooled, and, normal tissue from the corresponding 
patients were pooled. Pooling took place prior to protein preparation, to give separate tumour tissue 
and normal tissue pools. Membrane and cytoplasmic fractions were isolated from the pooled tissue 
biopsies, using published methods (109).  Briefly, the tissue was homogenized in ice-cold HEPES 
buffer (10mM HEPES, 1 mM EDTA, pH 7.4) using an Ultra Turrax homogenizer (Janke and Kunkel, 
Switzerland). The homogenate was subjected to differential centrifugation in order to collect a crude 
membrane fraction and a cytoplasmic fraction. The homogenate was centrifuged for 10 minutes at 
500Xg in a Sigma 302K (Sigma-Aldrich, St Louis, USA) at 4°C, in order to remove large debris. 
Subsequently, the supernatant was centrifuged for 75 min at 180, 000Xg at 4°C in a Beckman SW 
40 Ti (Beckman Coulter Inc, Calif). The pelleted membrane fractions were re-suspended and stored 
in 50 µL HEPES buffer containing a cocktail of protease inhibitors (cOmplete, Roche) (see appendix 
A), whereas cytoplasmic fractions were lyophilised. All fractions were stored at -70ºC, until further 
use. Unfortunately, no method was used to determine the effectiveness of the membrane and 
cytosolic fractionation. Pooled crude membrane fractions were re-suspended in HEPES buffer and 
centrifuged at 100,000 X g for 20 minutes at 4°C using a TLA-110 rotor in a Beckman Optima 
Ultracentrifuge (Beckman Coulter Inc, Calif) to pellet the membrane proteins. Membrane proteins 
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were solubilized in 400 µL of 2D lysis buffer (8M urea, 2M thiourea, 4% (w/v) CHAPS, 0.5% (w/v) 
NP-40, 10mM Tris-HCl pH 8.3). Lyophilised cytoplasmic protein fractions were re-suspended in 500 
µL of 2D lysis buffer. All samples were subsequently centrifuged at 13,000 X g in a benchtop 
centrifuge for 15 minutes, to pellet debris. Protein concentrations were determined using the 
Coomassie Plus Protein Assay Reagent (Pierce, USA) using BSA (bovine serum albumin) as a 
standard.  
2.2.3 Protein labeling, separation and gel imaging 
Protein lysates were fluorescently labelled with N-hydroxy succinimidyl (NHS) ester-derivatives of the 
cyanine dyes Cy2, Cy3 and Cy5 as previously described (110) . Briefly, 75µg of protein from the 
membrane fraction or 150 µg of protein from the cytoplasmic fraction were minimally labelled with 4 
pmol of dye per µg protein with either NHS-Cy3 or NHS-Cy5 (Table 2.1) for 30 min on ice in the 
dark, in as small a volume as possible. Reactions were quenched with a 20-fold molar excess of free 
lysine to dye for 10 min on ice. DTT was added to 65mM and the samples mixed appropriately (Cy3 
+ Cy5). The volume was made up for IPG strip rehydration (450 uL for 24 cm strips) to a final 
concentration of 65mM DTT (Dithiothreitol)
In parallel, equal amounts of protein from both normal and tumour were pooled and minimally 
labelled with Cy2, to serve as an internal standard (Table 2.1).  Samples are thereby in-gel linked to a 
common standard, giving accurate quantitation and separating gel-to-gel variation from inherent 
biological variation (Fig. 2.1).  
, 2% ampholytes/pharamalytes and bromophenol blue 
(Appendix A).  
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Figure 2.1: Protein labelling protocol. Proteins from normal and tumour lysates were fluorescently 
labelled with either Cy3 or Cy5. Equal amounts of protein lysates from normal and tumour origin 
were pooled and labelled with Cy2. This served as an internal control to minimize gel to gel variation. 
Relative protein abundance in tumour compared to normal was calculated as indicated (images 
courtesy of John Timms, Ludwig Institute for Cancer Research, University College of London). 
Table 2.1: Amount of labelled proteins separated on analytical gels. In gels 1-3, membrane protein 
preparations (denoted by m) were separated on triplicate gels, where N indicates protein from normal 
tissue and T indicates protein from tumour tissue. Proteins from normal and tumour tissue were 
reciprocally labelled in gel 2. In gels 4 - 7, cytoplasmic protein preparations (denoted by s
 Lysis and
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A+B/Cy2
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Fluorescence
Imaging
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) were 
separated on quadruplicate gels, where N indicates protein from normal tissue and T indicates 
protein from tumour tissue. Proteins from normal and tumour tissue were reciprocally labelled in gels 
5 and 7. In parallel, equal amounts of protein from both normal and tumour were pooled and 
minimally labelled with Cy2, to serve as an internal standard.  
Cy2 levels will be         
the same across            
all three gels. For 
each gel expression 
of a protein= 
(Cy3/Cy2)/(Cy5/Cy2) 
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Gel 
number Cy3 Cy5 
Cy2 
(internal standard) 
1 75 µg Nm 75 µg Tm 37.5 µg Nm and 37.5 µg Tm 
2 75 µg Tm 75 µg Nm 37.5 µg Nm and 37.5 µg Tm 
3 75 µg Nm 75 µg Tm 37.5 µg Nm and 37.5 µg Tm 
4 150 µg Ns 150 µg Ts 75 µg Ns and 75 µg Ts 
5 150 µg Ts 150 µg Ns 75 µg Ns and 75 µg Ts 
6 150 µg Ns 150 µg Ts 75 µg Ns and 75 µg Ts 
7 150 µg Ts 150 µg Ns 75 µg Ns and 75 µg Ts 
 
 
Protein separation was carried out using methods previously described (110), with minor 
modifications. Protein separation was carried out in a clean room ISO (International Organization for 
Standardization) class 6, reserved for protein handling, to minimize any contaminating proteins or 
fibres. IPG strips (pH range: 3 – 10, 24 cm) (GE Healthcare, United Kingdom)  were run on a 
Multiphor II electrophoresis unit (GE Healthcare, United Kingdom) for a total of 77 kVh at 17°C, to 
separate proteins on the basis of their iso-electric points. Equilibrated IPG strips were transferred 
onto 12.5% polyacrylamide gels poured between low-fluorescence glass plates. Gels were bonded to 
the inner plate using bind-saline solution (PlusOne, GE Healthcare, United Kingdom). IPG strips in 
the polyacrylamide gels were overlaid with 0.5% (w/v) low melting point agarose in 1X SDS 
electrophoresis buffer (Severn Biotech, United Kingdom) containing bromophenol blue. Gels were 
run in an Ettan DALT twelve electrophoresis unit (GE Healthcare, United Kingdom) at 2.8 Watts per 
gel until the dye front had run off the bottom. 2D gels were scanned between the plates directly after 
electrophoresis using a Typhoon 9400 multi-wavelength fluorescence imager and ImageQuant 
software (GE Healthcare, United Kingdom). Images were acquired using the optimal 
excitation/emission wavelengths for each fluorescent dye i.e. 488/520 nm for Cy2, 532/580 nm for 
Cy3 and 633/680 nm for Cy5. Low resolution scans (1000 µm) were first taken to optimise 
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photomultiplier tube (PMT) voltages to give maximum pixel values to within 10% for each Cy channel 
and below the saturation threshold of the imager. Final scans were performed at 100 µm resolution. 
2.2.4 Image analysis, post-staining, spot picking and digestion 
Images were analysed using DeCyder software v5.0 (GE Healthcare, United Kingdom) as previously 
described (110). Features matching on all images displaying a ≥2.0 -fold average increase or ≤ -2.0-
fold average decrease in abundance in cancer versus normal and with P-values ≤0.05 (Student T -
test) were selected for excision and MS analysis. To visualise separated proteins, the same gels were 
post-stained with colloidal Coomassie Brilliant Blue (CCB) G-250 using a modified version of the 
protocol by Neuhoff et al. (111,112).  Briefly, gels were fixed in fixing solution from 3 hours to 
overnight followed by three 30 min washes with distilled water. Staining solution was added and gels 
were left placed on shaker for 1 hour at room temperature.  An amount of 0.5 g/L crushed solid 
Coomassie Blue G-250 was added to the gel in staining solution and placed on a shaker for up to 3 
days at room temperature. Gels were then rinsed in distilled water and scanned on the Typhoon 
9400 imager using the red laser (633 nm) and no emission filter. CCB images were then matched 
with the corresponding Cy dye images using DeCyder software and a pick list of coordinates 
generated for excision using an Ettan automated spot picker (GE Healthcare, United Kingdom). For 
illustration purposes, images were also pseudo-coloured and superimposed using Adobe PhotoShop 
(Adobe Systems Inc., California). Excised protein spots from the post-stained gel were in-gel 
digested with modified trypsin (Promega, USA) and peptides extracted for MS analysis as previously 
described (103).  
2.2.5 MALDI-TOF MS peptide mass fingerprinting 
Peptide extracts (0.5 µL) were spotted onto a MALDI target with 1 µL of matrix solution (saturated 
aqueous 2,5-dihydroxybenzoic acid). Matrix-assisted laser-desorption/ionisation time-of-flight (MALDI-
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TOF) MS was performed using an externally calibrated Ultraflex TOF/TOF mass spectrometer 
(Bruker Daltonics) in the reflector mode. External calibration was achieved by using  commercially 
available Cal Mix standards (Applied Biosystems, United Kingdom) (details outlined in appendix A). 
The standards were spotted adjacent to sample on each plate used. After internal calibration using 
trypsin autolysis peaks, prominent peaks in the mass range m/z 500-5000 were used to generate a 
peptide mass fingerprint. Common contaminating peaks in all samples were excluded using the in-
house software ‘CommonContam’ (Developed by Dr Richard Jacobs, Ludwig Institute, UCL, 
London). Mass fingerprints were then searched against the updated IPI database using Mascot 
version 2.0.02 (Matrix Sciences). Identifications were accepted when a minimum of 6 peptide 
masses matched a particular protein (mass error of ±50 ppm allowing 1 missed cleavage), sequence 
coverage was >25%, MOWSE scores were higher than the threshold value (P=0.05), the predicted 
protein mass and pI agreed with the gel-based mass and pI and the proteins identified were human. 
  
2.2.6 Immunohistochemistry (IHC) 
Archived paraffin-embedded sections of tumour and normal tissue from up to 18 oesophageal cancer 
patients were used in order to confirm expression of a subset of proteins. Slides were heat-fixed for 
10 min on a heating block at 70 °C, de-paraffinised and rehydrated, followed by antigen retrieval by 
incubating slides in 10 mM sodium citrate buffer (pH 6) in a pressure cooker for 5 min. Sections were 
blocked for endogenous peroxidase activity by submerging the slides in 3% hydrogen peroxide for 20 
min. The slides were then incubated at room temperature with a 1/20 dilution of goat serum (Dako, 
California) for 30 minutes. Antibodies to annexin 2 (rabbit polyclonal) and GP96/HSP90B1 (goat 
polyclonal) (Santa Cruz Biotechnologies, Inc., California) were used at a dilution of 1/250 and 1/500, 
respectively. The monoclonal mouse antibody to gelsolin (clone GS-2C4, Sigma-Aldrich, St Louis, 
USA) was used at a dilution of 1/1000. The LSAB-2 detection system (DAKO, California) was used 
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according to the manufacturer’s instructions to detect the rabbit and mouse antibodies to annexin 2 
and Gelsolin. In the case of the goat antibody, a 1/600 dilution of biotinylated rabbit anti-goat 
immunoglobulins (DAKO, California) was used.  
Monoclonal mouse antibodies to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pyruvate 
kinase were used at a dilution of 1/400 and 1/100, respectively. Furthermore, the antigen retrieval 
method for the antibodies to GAPDH and pyruvate kinase involved incubating slides in 10 mM 
sodium citrate (pH 6) at sub-boiling point for 10 min. Also, the Envision Pollyalomer-HRP detection 
system (Dako, California) was used, according to manufacturer’s instructions, for the latter two 
mentioned antibodies as opposed to the LSAB-2 system.  
Omission of the primary antibody served as a negative control in each case. Sections were 
counterstained with haemotoxylin and subsequently dehydrated. The slides were independently 
evaluated by a qualified pathologist. 
2.2.7 Statistical evaluations and survival test 
In order to determine if there is an association between annexin 2 expression and patient survival, 59 
archived paraffin-embedded sections (Table A4 in Appendix A) of tumour tissue were stained for 
annexin 2, as described above. The statistical power of the study was calculated using published 
methods (113).  
The slides were independently evaluated by a qualified pathologist and annexin 2 staining in tumour 
tissue was scored as indicated in Table 2.2.  
Table 2.2: Criteria used by independent pathologist for scoring IHC slides. Slides were assigned a 
score of 0 to 4+ based on the percentage membrane staining observed in tissue section. 
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Intensity 
Percentage membrane staining in field of 
view 
0 less than 5% stained 
1+ between 5 and 25% stained 
2+ between 26 and 50% stained 
3+ between 51 and 75% stained 
4+ more than 75% stained 
  
 
The Kaplan Meier Survival test was applied to the data, using STATATM
 
 (version 8) (Stata 
Corporation, USA). The power of the sample size used in this study was calculated using the PS 
program (version 2.1.31). 
2.3 Results 
2.3.1 Protein quantitation and labeling 
As described in Materials and Methods, tissue from oesophageal tumour biopsies were pooled and 
similarly normal tissue, from the corresponding patients, were pooled prior to protein preparation, to 
yield a separate tumour tissue pool and a normal tissue pool. Tissue samples were pooled since 
biopsy sample were very small (most were approximately 0.07g in size) (Table 2.3). Subsequently 
membrane and cytoplasmic protein preparations were prepared and quantitated (Table 2.3). 
Table 2.3: Quantitation of protein fractions. Biopsies from normal and tumour tissue pools were 
weighed, prior to processing into membrane and cytoplasmic fractions. The corresponding protein 
preparations were subsequently quantitated and fractions from tumour biopsies were diluted to their 
equivalent counterparts as outlined in Table 2.1. 
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Pool 
Normal  
(pool of 44 patients) 
Tumour  
(pool of 44 patients) 
Mass (g) 3.14 3.07 
Fraction membrane soluble membrane soluble 
Concentration 
(µg/µl) 
0.885 0.855 2.163 1.183 
  
Although, the amount of tumour and normal biopsies were similar, the yield from the tumour biopsies 
was higher. Nevertheless, protein fractions from tumour biopsies were diluted to the same 
concentration as their normal counterparts, labelled and separated, as previously outlined (Table 2.1). 
 
 
2.3.2 2D-DIGE and MS protein expression profiling  
2D-DIGE analysis was used to examine changes in protein expression in pooled biopsy samples of 
primary oesophageal tumours and adjacent normal oesophageal tissue with the aim of identifying 
potential biomarkers or therapeutic targets for oesophageal cancer. In order to improve proteomic 
coverage, samples were fractionated into crude membrane and cytoplasmic fractions by 
ultracentrifugation. Separation of proteins on large format 2D-gels allowed the resolution of ~2500 Cy 
dye-labelled protein features in the crude membrane preparations (Fig. 2.2). Fluorescent images of 
differentially labelled (Cy3 and Cy5) proteins from normal and tumour membrane fraction were 
compared with a Cy2-labelled internal standard using the DeCyder image analysis software allowing 
accurate quantitation and separating gel-to-gel variation from tumour versus normal variation. 150 
significantly differentially expressed protein features were selected (P≤0.05) using a filtering threshold 
Un
ive
rsi
ty 
of 
Ca
pe
 To
n
  32 
of 2.0-fold up- or down-regulation (Fig. 2.3a). Post-staining of gels with CCB (Fig. 2.3b), however, 
allowed matching of only 71 of these features with the fluorescently-labelled features, suggesting that 
the expression levels of the other 79 features were too low for CCB detection and most likely, for 
successful MS-based identification. Similarly, ~3000 Cy dye-labelled features were identified from 
gels on which the proteins from the cytoplasmic fraction were resolved (Fig. 2.4). Fluorescent images 
of differentially labelled cytoplasmic proteins from normal and tumour samples were compared and 
55 protein features were shown to be significantly differentially expressed (P≤0.05) when filtering 
using a 2.0-fold threshold (Fig. 2.5a). CCB post-staining (Fig. 2.5b) allowed detection of only 32 of 
these features, again reflecting low protein levels in some gel spots. The matched protein spots were 
subsequently picked, digested with trypsin and subjected to MALDI-TOF MS peptide mass 
fingerprinting for identification. 
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Figure 2.2: Comparison of the grayscale images depicting the protein profile of (a) a crude 
membrane protein fraction from oesophageal tumour tissue, labelled with Cy 3 and (b) a crude 
membrane protein fraction from normal oesophageal tissue, labeled with Cy 5. Proteins differentially 
expressed by 2-fold (P<0.05) are outlined in red. Spot numbers are indicated for proteins identified by 
MALDI-MS and peptide mass fingerprinting. Molecular weight (MW) range is indicated on the left 
and pH range on the top of the image. 
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Figure 2.3: (a) Merged Cy dye image of a crude membrane protein fraction from oesophageal 
tumour tissue, labeled with Cy 3 (red) and a crude membrane protein fraction from normal 
oesophageal tissue, labeled with Cy 5 (blue). (b) The same gel was post-stained with colloidal 
coomassie blue. Molecular weight (MW) range is indicated on the left and pH range on the top of the 
image. 
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Figure 2.4: Comparison of the grayscale images depicting the protein profile of (a) cytoplasmic 
protein fraction from oesophageal tumour tissue, labeled with Cy 5 and (b) cytoplasmic protein 
fraction from normal oesophageal tissue, labeled with Cy 3. Proteins differentially expressed by 2-fold 
(P<0.05) are outlined in red. Spot numbers are indicated for proteins identified by MALDI-MS and 
peptide mass fingerprinting. Molecular weight (MW) range is indicated on the left and pH range on 
the top of the image. 
 
 
 
 
                
                 
         
a b
pH range    3                                                                 10              3                                                                 10 
MW range (kDa) 
100 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
  36 
 
 
 
 
 
 
 
Figure 2.5: (a) Merged Cy dye image of cytoplasmic protein fraction from oesophageal tumour 
tissue, labeled with Cy 5 (blue) and cytoplasmic protein fraction from normal oesophageal tissue, 
labeled with Cy 3 (red). (b) The same gel was post-stained with colloidal coomassie blue. Molecular 
weight (MW) range is indicated on the left and pH range on the top of the image. 
 
A total of 37 differentially expressed protein features corresponding to 24 gene products were 
identified from the crude membrane fraction (Table 2.4) and 26 features corresponding to 18 gene 
products were identified from the cytoplasmic fraction (Table 2.5). Several proteins were identified in 
more than one gel spot (Figure 2.2 and Table 2.4), possibly reflecting variable post-translational 
modification of these proteins. There was some overlap in the proteins identified from both the crude 
membrane and cytoplasmic fractions and these are highlighted in Tables 2.4 and 2.5.  
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Table 2.4: Summary of differentially expressed proteins in tumour compared to normal (from the membrane fraction) identified by MALDI-MS. (a) Average 
ratio: (-) indicates protein is down-regulated in tumour compared to normal and (+) indicates protein is up-regulated in tumour compared to normal (b) Spot 
number: Refers to spot numbers in Figure 2.2 (c) IPI number: International protein index reference number (d) predicted pI according to protein database (e) 
Molecular weight in Daltons according to protein database (f) pI according to position on gel (g) Molecular weight in Daltons according to position for gel (h) 
Number of peptides matching the top hit from Mascot Daemon programme versus the total number of masses submitted (i) Amino acid sequence coverage 
for the identified protein. *, ** and *** highlight proteins that overlap with proteins identified from the cytoplasmic fraction (see Table 2.5). 
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Tumour/Normal
Av. Ratio a Spot No. b Name IPI No. c Chromosome pI (pred) d Mw (pred) e pI (gel) f Mw (gel) g Score h %Cov i
-8.77 1118 Desmin ** IPI00465084 2q35 5.21 53588 5.17 57170 230 60
-7.05 1105 Desmin ** IPI00465084 2q35 5.21 53588 5.08 53588 286 69
-6.7 2096 Myosin regulatory light chain 2, smooth muscle isoform IPI00220278 20q11.23 4.94 19894 4.54 19894 88 77
-5.29 1465 Tropomyosin 2 (beta) isoform 2 IPI00220709 9p13.2-p13.1 4.63 33027 4.31 33027 91 41
-4.26 508 Glutaminyl t-RNA synthetase IPI00026665 3p21.3-p21.1 6.71 88655 7.97 75659 66 16
-3.74 915 Coronin (Actin Binding protein 1C) IPI00008453 12q24.1 6.65 53899 7.91 53809 72 23
-3.51 715 Keratin 10 IPI00295684 17q21 5.09 59020 7.4 68882 148 33
-3.45 1117 Desmin ** IPI00465084 2q35 5.21 53588 5 53588 64 18
-2.99 423 Keratin 10 IPI00295684 17q21 5.09 59020 6.32 78098 82 25
-2.79 1415 Actin  Aortic Smooth Muscle IPI00008603 10q23.3 5.23 42381 5.08 42294 161 65
-2.79 1434 Actin Gamma Enteric Smooth Muscle IPI00025416 2p13.1 5.31 42249 5.97 42249 136 56
-2.71 471 Gelsolin Isoform B IPI00377087 9q33 5.58 80876 5.96 80876 135 33
-2.63 958 T-complex protein, ETA subunit IPI00018465 2p13.2 7.55 59842 8.46 61318 78 23
-2.6 666 Human serum Albumin precursor IPI00022434 4q11-q13 5.92 71317 5.8 71317 87 27
-2.6 907 Keratin Type 2 cytoskeletal 5 IPI 00009867 12q12-q13 8.14 62651 7.73 63211 222 39
-2.59 1106 Desmin ** IPI00465084 2q35 5.21 53588 5.24 53588 247 60
-2.44 676 Human serum Albumin precursor IPI00022434 4q11-q13 5.92 71317 5.91 70076 92 25
-2.4 268 Plasminogen precursor IPI00019580 6q26 7.04 93247 7.9 93247 76 16
-2.3 99 Collagen alpha 2(VI) IPI00073454 21q22.3 5.7 88373 5.68 91401 69 12
-2.3 470 Gelsolin Isoform B IPI00377087 9q33 5.58 80876 5.83 80876 64 17
-2.25 273 Plasminogen precursor IPI00019580 6q26 7.04 93247 8 93247 68 16
-2.09 1390 Actin, Cytoplasmic 1 * IPI00021439 7p15-p12 5.29 42052 5.28 42052 101 58
-2.02 2159 Myosin light polypeptide 6, smooth muscle and non-muscle IPI00029208 12q13.2 4.46 16990 4.14 12770 112 50
-2.01 1170 Tubulin Beta-2 chain IPI00007752 6p25 4.79 50255 4.65 50255 92 36
2.06 566 Serotransferrin Precursor IPI00022463 3q22.1 6.81 79280 7.5 79280 122 27
2.14 1728 Pyruvate kinase 3 isoform 2 IPI00220644 15q22 7.6 58538 6.01 34964 84 23
2.15 925 Keratin 6B IPI00293665 12q12-q13 8.09 60247 4.56 62134 134 24
2.19 572 Serotransferrin Precursor IPI00022463 3q22.1 6.81 79280 7.47 79280 101 25
2.42 1109 Pyruvate kinase 3 isoform 1 IPI00383237 15q22 7.95 58701 7.67 57170 142 47
2.55 544 Serotransferrin Precursor IPI00022463 3q22.1 6.81 79280 7.61 79280 129 26
2.62 602 Keratin 10 IPI00295684 17q21 5.09 59020 5.1 59020 101 27
2.69 444
HSP90B1; GRP94; Endoplasmin precursor;Tumour rejection 
antigen (gp96) IPI00027230 12q24.2-q24.3 4.76 92696 4.92 77481 138 28
2.94 842 Keratin 10 IPI00383111 17q21 5.01 57384 4.26 64990 91 26
3.06 670 Human serum Albumin precursor IPI00022434 4q11-q13 5.92 71317 6.47 71317 189 40
3.11 1707 Annexin A2 isoform 2 ** IPI00455315 15q21-q22 7.57 38808 7.54 36282 76 37
3.23 448 HSP90B1; GRP94; Endoplasmin precursor;Tumour rejection 
antigen (gp96)
IPI00027230 12q24.2-q24.3 4.76 92696 5.04 77379 138 28
7.74 1800 Glyceraldehyde 3 phosphate dehydrogenase IPI00219018 12p13 8.57 36201 8.04 36201 62 19  
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Table 2.5: Summary of differentially expressed proteins in tumour compared to normal (from the cytoplasmic fraction) identified by MALDI-MS. (a) Average 
ratio: (-) indicates protein is down-regulated in tumour compared to normal and (+) indicates protein is up-regulated in tumour compared to normal (b) Spot 
number: Refers to spot numbers in Figure 2.4 (c) IPI number: International protein index reference number (d) predicted pI according to protein database (e) 
Molecular weight in Daltons according to protein database (f) pI according to position on gel (g) Molecular weight in Daltons according to position for gel (h) 
Number of peptides matching the top hit from Mascot Daemon programme versus the total number of masses submitted (i) Amino acid sequence coverage 
for the identified protein. *, ** and *** highlight proteins that overlap with proteins identified from the membrane fraction (see Table 2.4). 
Tumour/Normal
Av. Ratio a Spot No. bName IPI No.  C Chromosome pI (pred)  d Mw (pred) e pI (gel) f Mw (gel) g Score  h %Cov  i
-4.47 1454 Creatine Kinase B chain IPI00022977 14q32 5.34 42902 5.34 42902 72 34
-3.96 949 Tumour related protein IPI00297056 1q21 5.73 53740 6.31 95919 115 29
-3.84 1468 Creatine Kinase B chain IPI00022977 14q32 5.34 42902 5.18 51668 158 49
-3.3 769 Protein-glutamine glutamyltranferase IPI00300376 20q11.2 5.62 76926 6.26 110724 149 28
-2.96 1451 VAT-1  (vesicle amine transport) IPI00156689 17q21 5.88 42122 6.3 52441 69 34
-2.88 1513 Actin, Cytoplasmic 1   * IPI00021439 7p15-p12 5.29 42052 5.19 48569 79 39
-2.86 1493 Leukocyte elastase inhibitor; SERPINB1 IPI00027444 6p25 5.9 42829 6.31 49417 66 34
-2.34 209 Smooth Muscle  and Non-muscle Myosin alkali light chain IPI00335168 12q13.13 4.56 17090 5.36 178953 81 39
-2.25 1523 Acetyl-CoA Acetyltransferase, cytosolic IPI00291419 6q25.3-q26 6.47 41838 7.09 47616 89 28
-2.18 1561 Hurpin; serpinB13 IPI00006560 18q21.3-q22 5.48 44305 5.37 45542 81 34
-2.18 1207 Desmin   ** IPI00465084 2q35 5.21 53588 4.95 72700 118 31
-2.16 323 Alpha 2 Macroglobulin IPI00465313 12p13.31 6.06 167505 5.38 158910 64 11
-2.16 1512 Actin, Cytoplasmic 1   * IPI00021439 7p15-p12 5.29 42052 4.8 48689 60 32
-2.1 1176 Fibrinogen IPI00219713 4q28 5.7 50092 5.28 75263 94 31
-2.09 1495 Leukocyte elastase inhibitor; SERPINB1 IPI00027444 6p25 5.9 42829 6.02 49173 100 38
-2.08 320 Alpha 2 Macroglobulin IPI00465313 12p13.31 6.06 167505 5.45 159304 185 21
-2.05 316 Alpha 2 Macroglobulin IPI00465313 12p13.31 6.06 167505 5.33 160094 166 19
-2.04 324 Alpha 2 Macroglobulin IPI00465313 12p13.31 6.06 167505 5.5 167505 112 15
2.04 1876 Glutathione S-transferase IPI00019755 10q25.1 8.14 33430 6.39 27626 87 31
2.11 1709 Annexin A2   *** IPI00455315 15q21-q22 7.57 38808 7.5 38808 76 33
2.11 1961 Nicotinamide N-methyltransferase IPI00027681 11q23.1 5.56 30011 5.23 23579 73 26
2.23 1913 14-3-3 Protein Zeta or Delta IPI00021263 8q23.1 4.73 27899 4.24 25713 110 57
2.46 1737 Aldo-keto Reductase Family member B10 IPI00105407 7q33 7.12 362266 7.51 36226 70 28
4.78 1548 Creatine Kinase M chain IPI00027487 19q13.2-q13.3 6.77 43302 7.51 46338 160 45
5.85 1546 Creatine Kinase M chain IPI00027487 19q13.2-q13.3 6.77 43302 7.4 46915 87 21
9.34 1551 Creatine Kinase M chain IPI00027487 19q13.2-q13.3 6.77 43302 7.6 46109 209 49  Un
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Figure 2.6: Gene ontology for all identified proteins that displayed altered expression in OSCC 
compared to normal tissue based on data from tables 2.4 and 2.5. (a) Pie graph illustrating the 
biological processes that the identified proteins are implicated in (b) Pie graph illustrating the 
biological compartment of origin of the identified proteins (images were kindly generated by software 
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designed by Dr Richard Jacob, Ludwig Institute for Cancer Research, University College of London, 
United Kingdom) 
The data set of proteins identified to be differentially expressed were categorized according to both 
biological processes (Fig 2.6a) that the proteins contribute to; as well as according to the 
compartment the proteins are localized in (Fig 2.6b).   
The differentially expressed proteins from the membrane fraction identified by MALDI-MS analysis 
comprised a small range of functional categories, including cytoskeletal/attachment/ extracellular 
matrix (ECM) elements, metabolic enzymes, and stress-related proteins. It is probably not surprising 
that the cytoskeletal/attachment/ ECM proteins comprised the largest category since these proteins 
are probably present at relatively high concentrations in cells, facilitating their detection in the system 
used. These include myosin, tropomyosin, actin, collagen, coronin, desmin and tubulin, most of 
which are decreased in tumour tissue (Table 2.4).   
Human serum albumin precursor (Spots numbered 666 and 676 in Table 2.4 and Fig. 2.2) displayed 
decreased expression in tumour tissue compared to normal tissue. However, in an apparent anomaly 
further down in Table 2.4, this same protein (human serum albumin precursor) was over-expressed 
3-fold in tumour, relative to normal tissue (spot number 670 in Table 2.4 and Fig. 2.2). This apparent 
contradiction presumably reflects differential post-translational processing of this protein in tumour 
tissue compared to normal tissue since the same protein occurs at the same molecular weight, but 
different pI positions. A similar result is observed for keratin 10 (spots numbered 423 and 715 versus 
spots numbered 602 and 842 in Table 2.4 and Fig. 2.2). 
It was also observed that the levels of two glycolytic enzymes (glyceraldehyde 3 phosphate 
dehydrogenase - Table 2.4 and Fig 2.2: Spot 1800 and pyruvate kinase - Table 2.4 and Fig 2.2: 
Spots 1109 and 1728) were markedly elevated in tumour tissue compared to normal tissue. The two 
spots, identified for pyruvate kinase, represent two different isoforms. 
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A decrease in glutaminyl t-RNA synthase levels, in tumour tissue compared to normal in the 
membrane fraction, was also observed and although involved in transcription there is also evidence 
to suggest that this protein inhibits pro-apoptotic mediators (114). 
The proteins displaying altered expression levels in normal and tumour tissue from the cytoplasmic 
fraction identified by MALDI-MS displayed a range of functional categories similar to that observed for 
the membrane fraction i.e. cytoskeletal/attachment/ extracellular matrix (ECM) elements, 
metabolism, stress-related proteins and signal transduction. The cytoskeletal/attachment/ 
extracellular matrix (ECM) proteins represented the bulk of the proteins identified. The metabolic 
enzymes identified in the cytoplasmic fraction are primarily involved in metabolism of xenobiotic 
compounds, in contrast to the glycolytic enzymes identified in the membrane fraction. Aldo-keto 
reductase, glutathione-S-transferase and nicotinimide N-methyltransferase are involved in 
detoxification of foreign compunds and although no function exists for VAT-1, it is believed to be part 
of the alcohol dehydrogenase family. Furthermore, acetyl Coenzyme A acetyltransferase is involved 
in ketone body metabolism, for the production of energy. 
The stress related protein, cornulin (identified as tumour related protein in Table 2.5), which is a 
squamous epithelial heat shock protein and is part of a novel heat shock response in squamous 
epithelium was down-regulated in tumour similar to the observation in oral squamous cell carcinoma 
(115,116). 
14-3-3 ζ (or Δ) was identified to be up-regulated in the cytoplasmic fraction of tumour tissue 
compared to normal and plays a role in signal transduction, mitogenesis, cell survival, cell cycle 
control and apoptosis (117).  
Other proteins that displayed altered levels of expression included, human serum albumin precursor, 
plasminogen precursor, fibrinogen and serotransferrin. Their presence in these samples could reflect 
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varying levels of serum contamination in the biopsy samples. Also, alpha 2 macroglobulin, hurpin 
(Serpin B13) and leukocyte elastase inhibitor fall under the umbrella of protease inhibitors that are 
usuall present in the serum or cytoplasm and are thought to play roles in proliferation, differentiation 
and regulation (118-120). 
Of the differentially expressed proteins listed in Table 2.4 and 2.5, five were selected for further 
investigation (Table 2.6). These were annexin 2 and HSP90B1 (also known as GRP94, endoplasmin 
and tumour rejection antigen), GAPDH and pyruvate kinase, which displayed increased expression in 
tumour tissue relative to normal. Gelsolin was also selected for further investigation, but this protein 
displayed reduced expression in tumour tissue relative to normal (Fig. 2.7 and Table 2.6).  
 
Table 2.6: Summary of differentially expressed proteins selected for further investigation. Average 
ratio: Unless otherwise indicated, an increase in expression was observed in tumour tissue compared 
to normal, where (-) indicates protein is down-regulated in tumour compared to normal. HSP90B1, 
pyruvate kinase and gelsolin appear twice on Table 2.4 therefore have two average ratios.  
  
Tumour/Normal
Ave ratio Name
3.11 Annexin 2 
2.69 and 3.23 GP96
7.74 GAPDH
2.14 and 2.42 Pyruvate kinase
-2.3 and -2.71 Gelsolin  
HSP90B1 (GP96 in Table 2.6), which belongs to the HSP90 family, was selected for further 
investigation because this protein has previously been associated with prostate and breast cancer 
(121,122). Altered gelsolin expression was previously observed in prostate and ovarian cancer 
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(123,124) and altered annexin A2 expression has been reported for human gliomas and pancreatic 
cancer  (125,126).  
Furthermore, both gelsolin and annexin 2 are involved in actin dynamics and could impact on 
important cellular processes such as cell motility and invasion (127-130). The other two proteins of 
interest, GAPDH and pyruvate kinase, both involved in the glycolytic pathway, displayed elevated 
expression in tumour tissue. The observation that tumour tissue displays elevated levels of glycolytic 
enzymes, and thus glycolysis, is a well documented phenomenon. The elevated glycolysis, and 
dependence of tumour tissue on glycolysis for energy is termed the Warburg effect (131). This 
observation will be explored in more detail in Chapter 4. 
In Fig 2.7, the Decyder Software analysis depicts a 3-dimensional visualisation of the spots, 
reflecting the quantitation of the spots, (highlighted by arrows) illustrating that annexin 2 (Fig 2.7a), 
HSP90B1 (Fig 2.7c), GAPDH (Fig. 2.7g) and pyruvate kinase (Fig. 2.7i) expression is increased in 
tumour tissue compared to normal tissue. Gelsolin expression (Fig 2.5e), however, is decreased in 
tumour compared to normal tissue. This information is represented graphically in Fig. 2.7 b,d, f, h 
and j showing the standardized abundance of each protein in tumour tissue compared to normal 
tissue, where each point represents the protein spot obtained in triplicate gels. The data in panels b, 
d, f, h and j of Figure 2.7 shows the differences between the different gels, providing information 
about the spread, and therefore the consistency of data between the gels. The graphical 
representation further illustrates that the expression of annexin 2, HSP90B1, GAPDH and pyruvate 
kinase expression are significantly increased (> 2-fold) in tumour compared to normal tissue while the 
expression of gelsolin is significantly reduced (> 2-fold) in tumour compared to normal tissue (where 
P< 0.05). MALDI-MS generated mass spectra of each digested protein (Appendix B: Fig. B1 – Fig. 
B5) were internally calibrated with trypsin autolysis peaks and peptide mass fingerprints were 
analysed, as described in the methods section.  
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Figure 2.7: Depicts Decyder Software analysis of the following differentially expressed proteins: 
Annexin 2 (a and b), HSP90B1 (c and d), Gelsolin (e and f), GAPDH (g and h) and Pyruvate kinase 
(I and j). The top panels in a, c, e, g and i highlight the protein spot of interest in purple. The bottom 
panel in a, c, e, g and i; graphically represent the protein expression levels in tumour compared to 
normal (indicated by the arrows). The standardized abundance (y-axis) of the proteins’ expression in 
tumour (blue points) compared to normal (red points) (x-axis) is shown in b, d, f, h and j. The points 
are representative of the protein spot in three separate gels and the difference in expression is 
normaltumour
Annexin2
a b
GP96 
c d
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GAPDH
normaltumourPyruvate kinase
i j
HSP90B1 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  46 
significant, where P<0.05 (see Table 2.4). The blue line connects the points representative of the 
protein spot in gel 2 (Table 2.1). 
 
 
2.3.3  
2.3.4 IHC of selected targets 
IHC staining of archived paraffin-embedded tissue was used to assess the expression of annexin 2, 
HSP90B1 and gelsolin in oesophageal tumours and paired normal tissues from 18 patients. Annexin 
2 expression was markedly elevated in tumour tissue compared to normal tissue (Fig. 2.8 a-c) in all 
18 sections examined, confirming the results observed by 2D-DIGE analysis.  Furthermore, the 
plasma membrane of dysplastic epithelial cells stained strongly for annexin2, relative to the weak 
annexin 2 staining observed in normal epithelial cells (Fig. 2.8 a and b). The strong increase in 
annexin 2 staining, observed in early dysplasia, prompted us to examine whether annexin 2 was 
linked to survival status (Fig. 2.8 b). However, no statistically significant correlation with survival 
status was observed in a larger cohort, of 59 patients (Fig 2.9). Examining a larger cohort of patients 
would have improved the power of the study; ideally at least 100 patients would have improved the 
power from 0.568 (for the 59 patients examined) to 0.793 (Table 2.7).  This would allow us to draw a 
statistically significant conclusion either way, but unfortunately, no further patient samples were 
available. 
HSP90B1 expression was relatively weak in both normal epithelium and tumour tissue (Fig. 2.8d, e 
and f). All sections displayed negative to weak membrane expression of HSP90B1 in the normal 
epithelia, whereas the tumour tissue displayed a weak cytoplasmic staining, suggesting a possible 
increase in expression, and a change in sub-cellular localisation, both of which require further 
investigation. No gelsolin staining was observed in normal epithelial cells, whereas a weak 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
  47 
cytoplasmic stain was observed for gelsolin in tumour tissue (Fig. 2.8g and h), which is contrary to 
the 2D-DIGE data observed (Table 2.6).  Furthermore, the muscle and stromal tissue stained 
strongly positive for gelsolin in both normal and tumour tissue.  
            
Figure 2.8: Immunohistochemical staining of annexin 2, HSP90B1 and gelsolin (a) Weak membrane 
staining of annexin 2 in normal epithelia [100X] (b) Strong membrane staining of annexin 2 in 
dysplastic epithelia [100X] (c) Intense membrane staining of Annexin 2 in invasive carcinoma 
characterized by “keratin pearls” [100X] (d) Weak membrane staining of HSP90B1 in normal 
epithelia [40X] (e) Magnification of (d) [100X] (f) Cytoplasmic blush of HSP90B1 in invasive 
carcinoma [100X] (g) Negative epithelial staining for gelsolin in normal epithelia [40X] (h) 
Cytoplasmic blush of gelsolin in invasive carcinoma [40X]. Where [ ] indicates total magnification, L 
indicates Lumen, E indicates epithelia and S indicates Stroma. 
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Figure 2.9: Kaplan Meier Survival curve illustrating the proportion of patients surviving in years 
based on annexin 2 status, where the blue line indicates patients negative for annexin 2 staining and 
the red line indicating patients with positive annexin 2 staining. Total number of events analysed were 
59 (59 patients, details outlined in Table A4) from which no statistically significant correlation exists 
between annexin 2 staining and survival (p=0.38). This data indicates that annexin 2 over-expression, 
in OSCC patient tumour tissue does not correlate with a decrease in survival status.  
Table 2.7: Calculated power and sample size. Hypothesis: increased annexin 2 expression is 
associated with poor patient survival. This study included 59 subjects/slides (n), an accrual interval 
(A) of 16.1 time units, and additional follow-up (F) after the accrual interval of 0 time units.  Prior data 
indicate that the median survival time (m1 and m2) on the control treatment is 1.4 time units.  If the 
true median survival times on the control and experimental treatments are 1.4 and 2 time units, 
respectively, we will be able to reject the null hypothesis that the experimental and control survival 
curves are equal with probability (power)  of 0.568.  The Type I error probability (α) associated with 
this test of this null hypothesis is 0.05. If the study included 100 subjects/slides (n) then we would 
have been able to reject the null hypothesis that the experimental and control survival curves are 
equal with probability (power) of 0.793. 
          
      α       n     m1      m2      A      F       M   Power 
0.05 59 1.4 2 16.1 0 2.5 0.568 
0.05 100 1.4 2 16.1 0 2.5 0.793 
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Figure 2.10: Immunohistochemical staining of pyruvate kinase (PK) and GAPDH: (a) Weak staining 
of PK in normal tissue [100X] (b) intense staining of PK in tumour tissue, characterized by the 
disorganized tissue architecture where boundaries for stroma and epithelia are not clearly defined 
[400X] (c) weak cytoplasmic GAPDH staining in normal tissue, with strong nuclear staining [100X], 
compared to  (d) intense GAPDH staining [40X] in better differentiated tissue surrounding the keratin 
pearl in comparison to poor staining in less differentiated tissue, mimicking normal epithelial tissue 
architecture (e) Inset of the staining at the periphery of the keratin pearl [100X].  [ ] indicates total 
magnification, L indicates Lumen, E indicates epithelia and S indicates Stroma. 
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We also examined the expression levels of GAPDH and pyruvate kinase, which were both observed 
to show increased levels in tumour tissue in our 2D-DIGE analysis. Figure 2.10 shows both pyruvate 
kinase (PK2) (Fig. 2.10 a and b) and GAPDH (Fig. 2.10 c-e) display markedly increased levels in 
tumour tissue compared to normal tissue. All the sections examined displayed the same staining 
pattern. 
The increase in GAPDH and PK2 levels were observed in early dysplasia. Furthermore, better 
differentiated cells displayed stronger staining than poorly differentiated cells. It was interesting to 
note that not only did GAPDH present with cytoplasmic staining, but a large proportion of the cells 
showed nuclear localisation (Fig. 2.10 c-e). Interestingly, as cells become less differentiated, the 
staining changed from cytoplasmic and nuclear to just nuclear. 
Of the proteins identified, the increase in GAPDH and pyruvate kinase (enzymes involved in 
glycolysis) was of special interest and was further explored (see Chapter 4). 
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2.4 Discussion 
Proteomic approaches such as 2D-DIGE promise to facilitate the identification of proteins that could 
potentially be exploited for diagnostic or therapeutic purposes, and compliment the information 
generated using more established genomic approaches. In this study 2D-DIGE was used to identify a 
group of proteins that are differentially expressed in oesophageal tumour versus paired normal tissue 
from the same patients. 
Patient samples (biopsies) were exceptionally small (pinhead size), and not enough protein could be 
obtained from a single patient sample for use in 2D-DIGE. It was therefore necessary to pool 
samples, as outlined in Materials and Methods section. Although pooled samples yielded low 
statistical power, it still allowed within-group variability to be determined. An advantage is that the 
heterogeneous pools balance out inter-individual differences and highlight biological variation 
between normal and tumour tissue (132). Technical replicates revealed good reproducibility as 
displayed by the consistency of protein spots between replicate gels (Fig.2.7), illustrating the low 
variability inherent to the technique used. 
Although the tissue samples in this study were separated into cytoplasmic and crude membrane 
fractions prior to 2D-DIGE, some proteins typically associated with the cytoplasm were identified in 
the membrane fraction, including pyruvate kinase and GAPDH (Table 2.4). We cannot exclude the 
possibility that the crude membrane fractions were contaminated with cytoplasmic cell components 
despite the extensive washing steps performed. However, it is also possible that the presence of 
these proteins in the membrane preparation may reflect  their association with structures, which co-
purify with the membrane fraction, as previously reported for pyruvate kinase (133,134) and GAPDH 
(135,136).  
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The increased levels of glycolytic enzymes in tumour tissue observed here has been observed before 
for other cancers (137-139). Presumably this reflects the shift from mitochondrial oxidative 
phosphorylation to aerobic glycolysis for glucose metabolism, as originally observed by Warburg 
(131). Our observation that oesophageal cancer cells display elevated levels of glycolytic enzymes 
suggest that this cancer also displays altered glucose metabolism, which presents unique 
therapeutic opportunities as reported elsewhere for lung and breast cancer (139). The opportunity to 
exploit this for therapeutic intervention in oesophageal cancer was investigated and will be reported in 
Chapter 4. 
Proteins that displayed altered levels of expression in tumour compared to normal tissues, but were 
not further investigated in this study, included cytoskeletal/attachment/ extracellular matrix (ECM) 
elements and cell signalling molecules.  
14-3-3 ζ plays a role in signal transduction, mitogenesis, cell survival and cell cycle control; however, 
recently it has also been shown that an increase in 14-3-3 ζ results in decreased apoptotic potential 
(117). These oncogenic characteristics have led to the suggestion that increased expression of 14-3-
3 ζ is associated with tumour promotion. Increased levels of 14-3-3 ζ observed in the cytoplasmic 
fraction of tumour tissue in this study is consistent with reports of elevated expression of this protein 
in breast cancer, lung cancer and gastric cancer, although the exact role of 14-3-3 ζ in the 
development of these cancers is poorly understood (140-143).   
Collagen alpha 2 (iv) (also type IV collagen) is the major structural component of basement 
membranes, in a complex network with laminins, proteoglycans and entactin/nidogen (144,145). 
Previously, collagen alpha 2 (iv)  has been shown to display diminished expression in colorectal 
cancer as well as in prostate cancer (146).  Ikeda et al showed that the decreased levels of type IV 
collagen in colon cancer is due to hypermethylation of the promoter region (147).  
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The cytoskeletal components of a cell play an important role in co-ordinated and directed movement 
displayed by many cell types. This complex network of proteins includes a number of the proteins 
identified in this study including actin, tubulin, desmin coronin, tropomyosin, gelsolin, T-complex 
protein ETA subunit and myosin (classes detailed in Table 2.4 and 2.5). Coronin, gelsolin and 
tropomyosin are actin binding proteins, whereas T-complex protein ETA subunit is a chaperonin 
facilitating actin and tubulin folding (148).  
Winston et al showed that down-regulation of gelsolin correlates with the progression of breast 
carcinoma (149), whereas an adverse prognostic effect was observed for non-small cell lung cancer 
with increased and variable levels of gelsolin (150). In this study, we were unable to confirm the 
decreased level of gelsolin in tumour tissue, as observed by 2D-DIGE. This was due to the low level 
of gelsolin staining in normal oesophageal epithelium. While this could be due to an inactive antibody 
or poor quality sections, the strong, specific staining observed in muscle tissue of the same sections, 
ruled out these possibilties (151). The reason for the low levels of staining for gelsolin staining is 
unknown. 
Actin, tubulin, desmin coronin, tropomyosin, gelsolin, T-complex protein ETA subunit and myosin all 
displayed a decreased level in tumour compared to normal. The expression  of these cytoskeletal-
associated proteins and intermediate filaments, reflect their role in morphologic and functional 
differentiation status (152). Although no consistent differences in cytoskeletal structure between 
normal and tumour cells have been identified, the possibilty that altered levels of these cytoskeletal 
elements contributes to the development of cancer, cannot be excluded (152). 
Although annexin 2 can bind actin directly (thus forming part of the complex network that extends 
throughout the cytoplasm), it is not always associated with actin, and instead, is recruited to sites of 
actin assembly at cellular membranes (153,154).  Annexin 2 is associated with dynamic actin 
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structures involved in phagocytosis, pinocytosis and migration (154). Annexin 2 (also known as p36 
and calpactin 1) belongs to a family of calcium and lipid binding proteins that are expressed in a wide 
range of organisms from protists to vertebrates. Knockdown studies of annexin 2 in human glioma 
cells suggest that this protein plays an important role in cellular migration (125). The elevated 
expression of annexin 2 observed in tumour tissue by 2D-DIGE was validated in oesophageal tumour 
sections using IHC. 
The elevated expression of annexin 2 observed in this study suggests that annexin 2 may play a 
similar role in oesophageal cancer.  Furthermore, our results also suggest that alterations in annexin 
2 gene expression may be an early event in the neoplastic process in oesophageal cancer. Of the 18 
archived paraffin blocks that were analysed, 14 sections contained dysplastic tissue, all of which 
exhibited elevated annexin 2 levels.  The elevated expression of annexin 2 at an early stage of 
oesophageal neoplasia suggests that this protein could be explored further as a potential early marker 
for the development of OSCC. Analysis of whether annexin 2 levels correlated with patient survival, 
showed that the correlation was not significant (Fig. 2.9). Unfortunately, only 59 sections were used 
in the statistical analysis, reducing the power of the study and decreasing the possibility of identifying 
a positive correlation. By increasing the number of patients in the cohort, it is possible that a 
statistically significant, positive correlation may be obtained (Table 2.6). Unfortunately, this study was 
limited by the patient sample available and increasing the number of patients in the cohort was not 
possible. 
Keratins also form part of the intermediate filament family involved in the complex network of proteins 
that spread throughout the cytoplasm and play a role in maintaining cell architecture and structure 
(152). In an IHC study, Takahashi et al (155) reported that OSCC tissue displayed altered levels of 
keratin reactivity and distribution compared to normal oesophageal tissue.  Our results support this 
finding, where several members of the keratin family displayed altered levels in tumour compared to 
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normal tissue in OSCC patients. It is well established that keratin 10 expression is associated with 
keratinising cells in squamous cell carcinomas of epidermis, lung, bladder, cervix and oesophagus 
(156,157). Another keratin identified in this study is keratin 6b, an isomer of keratin 6. Keratin 6 is 
unusual in that it is considered a marker for cell proliferation (158,159), consistent with the increased 
levels observed in tumour tissue compared to normal in OSCC patients. Keratin Type 2 cytoskeletal 
5, also known as keratin 5, displayed decreased levels in tumour compared to normal tissue in 
OSCC patients, possibly reflecting differentiation status of the tissues used. In the neoplastic 
process, cells clearly change their profiles of keratins, reflected by the altered architecture.  
Plasminogen precursor, human serum albumin precursor (albumin), fibrinogen and alpha-2-
macroglobulin
Glutaminyl-tRNA synthetase (glutaminyl-tRNA ligase) is responsible for charging tRNA with L-
glutamine. Although this protein is primarily involved in protein synthesis, recent data reveals a 
regulatory role in apoptosis (160). Glutaminyl-tRNA synthetase is reported to have a pro-apoptotic 
role by interacting with, or blocking, its interaction with pro-apoptotic mediator, Daxx, the 
downstream kinase, ASK1 (apoptosis signal-regulating kinase) (160,161). One of the key molecular 
changes of a tumour cell is an ability to evade apoptosis (22). Reduced glutaminyl-tRNA synthetase 
 are found in the plasma, reflecting possible contaminating serum components in the 
membrane fraction. Levels of these proteins in tumour tissue compared to normal tissue were not of 
interest in this study as the altered levels were considered artefacts of serum contamination. Serum 
protein contamination was relatively inevitable, considering the amounts of blood attached to each 
biopsy used. Unfortunately, due to the method of biopsy collection, serum contamination could have 
been avoided if more washing steps were included prior to homogenisation. Due to the rapidity at 
which the samples thawed, care was taken minimise protein degradation, hence washing before 
homogenisation was not performed.  
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levels in tumour tissue compared to normal tissue, as observed in this study, would contribute to 
tumour cells’ resistance to apoptosis. 
Yagui-Beltran et al (115) demonstrated that normal squamous epithelia display a novel heat shock 
response, including changes in levels of protein-glutamine glutamyltransferase (transglutaminase-3) 
and cornulin.  These proteins may regulate normal cellular integrity in squamous cell epithelia and a 
decrease in their levels may result in the development of cancer (115).  
In this study, transglutaminase-3 displayed decreased levels in tumour tissue compared to normal in 
OSCC patients. This is in agreement with other studies reported by others, in which both proteomic 
and immunohistochemical data suggest transglutaminase-3 as a prognostic marker for OSCC 
(162,163).  
Tumour related protein or cornulin (Chromosome 1 open reading frame 10 -C1orf10) is known to be 
down-regulated in OSCC compared to normal tissue (116), as confirmed in this study. It has been 
reported that exogenous expression of cornulin inhibits cell proliferation, therefore reduced expression 
of cornulin would facilitate the neoplastic process (116). 
Multiple forms of creatine kinase exist (164). In our study a decrease in creatine kinase (B-chain- 
brain type) levels and an increase in creatine kinase (M-chain- muscle type) levels were observed in 
the cytoplasmic fraction. Creatine kinase is important in energy metabolism and generally found in 
high energy requiring tissues (165). Our study is not the first to describe decreased levels of brain 
type creatine kinase. Pretlow et al reported a decrease in creatine kinase in prostate cancer 
compared to benign prostatic hyperplasia (166). 
Acetyl-coA acetyltransferase is located in the cytosol and is involved in cholesterol and steroid 
synthesis as well as ketogenesis (167,168). It is intriguing that acetyl-coA acetyltransferase levels 
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show reduced expression in tumour tissue compared to normal tissue our study, considering the 
importance of sterol synthesis for membrane biosynthesis in rapidly dividing cells. 
Glutathione S transferase is an enzyme that is involved in xenobiotic metabolism (169). It is 
expressed in a wide range of tissues that includes the aorta, bone, breast, colon, oesophagus, 
foreskin, lung, ovary, pancreas, prostate, stomach, testis and uterus (170,171). Considering the 
broad spectrum of tissue expression, Board et al (170) suggested that it may have a significant 
housekeeping function, such as protection from oxidative stress. Considering the increased oxidative 
stress in tumour cells, the protective function of glutathione S transferase is consistent with the 
elevated expression of this protein in tumour tissue observed in this study. 
Nicotinimide n-methyltransferase, like Glutathione S transferase is also involved in metabolism of 
foreign compounds (172). Nicotinimide n-methyltransferase has shown to be elevated levels in 
gastric cancer tissue compared to its normal counterpart (173). It has also been identified as a serum 
marker for the identification of colorectal cancer (174). Considering that it displayed increased levels 
in OSCC compared to normal tissue in this study, its diagnostic significance as a serum marker in 
OSCC should be considered. 
Aldo-keto reductase family 1 B10 (AKR1B10), a member of the aldo-keto reductase superfamily. In 
addition to displaying an increased expression in OSCC in this study, it has also been shown to have 
elevated levels in lung squamous cell carcinoma and colorectal cancer (175,176). It functions mainly 
as part of the detoxification system and its overexpression has been associated with smoking in lung 
cancer (175). Furthermore, using a cultured colorectal cancer cell line as a model system, it was 
determined that AKR1B10 also plays a role in regulating cell proliferation (176).  Knocking down this 
gene, using small interfering RNA technology, resulted in a 50% decrease in cell growth suggesting 
that this protein could represent a credible therapeutic target (176). 
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Although serotransferrin precursor or transferrin is a secreted protein located in the plasma, it is 
usually bound to its receptor on the cell membrane (177,178), probably accounting for the presence 
of transferrin in the membrane fraction in this study. Transferrin is responsible for carrying iron from 
the intestine, reticuloendothelial system, and liver parenchymal cells to all proliferating cells in the 
body (177,178). The elevated level of transferrin observed in this study is consistent with the need for 
transferrin in cellular proliferation (179).  
The membrane protein VAT-1 (vesicular amine transporter 1) homolog, (also known as SLC18A1- 
solute carrier family 18) is located in membranes, but in this study, this protein was recovered from 
the cytoplasmic fraction. VAT-1 functions to accumulate cytosolic monoamines into vesicles, using 
the proton gradient maintained across the vesicular membrane (180). These vesicles could have 
fractionated with the cytoplasmic fraction in this study. Although no link to cancer development is 
known, it has been established that it can serve as a calcium-regulated activation marker for 
epithelial cells (181). 
Serpins are a group of proteins with similar structures that were first identified as a set of proteins 
able to inhibit proteases. The name serpin is derived from this activity - serine protease inhibitors 
(120). In our study we showed serpin B13 and serpin B1 had decreased levels in OSCC compared to 
normal tissue.  
Serpin B13 is responsible for inhibiting papain-like cysteine proteases (182) and is thought to play a 
role in cell proliferation and differentiation in keratinocytes (183,184). Our data is in agreement with 
literature reports as low levels of serpin B13 were observed in squamous cell carcinoma of the oral 
cavity compared with normal oral mucosa (184).  
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Serpin B1 is involved in regulating the activity of the neutrophil proteases elastase, cathepsin G, 
proteinase-3, chymase, chymotrypsin, and kallikrein-3 (185). Furthermore, it inhibits several 
intracellular proteases and displays anti-apoptotic activity (185).  
HSP90B1, also known as GRP94, endoplasmin and tumour rejection antigen, is an endoplasmic 
reticulum chaperone that belongs to the HSP90 family (186). Increased HSP90B1 levels are 
correlated with hepatitis B virus (HBV)-induced disease progression, where HSP90B1 levels are 
highest in hepatocellular carcinoma (HCC) tissues (187). From these results, Zhu et al proposed 
HSP90B1 as a good candidate for a diagnostic or prognostic biomarker for HBV infection and HBV-
induced diseases (187). HSP90B1 has been shown to be elevated in oesophageal cancer, however 
the validation of it’s expression was performed via western blot analysis (70,105). This study used 
IHC, allowing visualisation of the sub-cellular localisation of HSP90B1 levels. Although weak staining 
was observed in our study, the IHC analysis showed that HSP90B1 was moderately elevated in the 
cytoplasm of tumour tissue, suggesting that it may have potential as a biomarker for oesophageal 
cancer; however, this will require further investigation.   
Previous proteomic studies on oesophageal cancer have identified a number of proteins as 
differentially expressed. Methods used included Laser Capture Microdissection (LCM), to isolate 
proteins from whole cell lysates from one case (70,105,162). The proteins were then either subjected 
to conventional 2DE methods or 2D-DIGE linked to MS to identify the proteins (70,105,162,188).  
In our study we pooled samples, as described above, in order to overcome the inter-individual 
heterogeneity between oesophageal cancer patients. We are, however, confident that the differences 
in expression patterns displayed for proteins were significant as they were representative of the 
protein of interest’s expression in three separate gels and normalized with an internal standard 
(Figure 4b).  
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A total of 39 differentially expressed proteins were identified, which constituted a substantially 
different group of proteins to those in the studies reported by Qi et al (188), Zhou et al (70,105)  and 
Uemura et al (162). HSP90B1 was common to our study, Qi et al (188) and Zhou et al (70,105). 
The identification of transglutaminase-3 was shared between our study and Uemura et al  (162). 
To our knowledge none of the previous studies identified annexin 2 and gelsolin to be differentially 
expressed. We validated annexin 2, HSP90B1, gelsolin, GAPDH and pyruvate kinase expression 
using immuno-histochemical analyses. Previous studies have utilized western blot analyses to 
confirm protein expression patterns (105,188). However, IHC has the added advantage that it also 
provides information regarding localization of the protein during the tumourigenic process (162). 
In summary, this study has identified a number of proteins that are differentially expressed in tumour 
tissue compared to normal tissue from oesophageal cancer patients. Further functional studies of 
annexin 2 could validate its potential use as either an early diagnostic marker and/or prospective 
therapeutic target. Furthermore, this study highlights the importance of validating protein expression 
data obtained from proteomic studies using a method that permits the demonstration of the sub-
cellular localization.  
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3 Altered glycoprotein profile in OSCC cell line compared to an 
immortalized normal oesophageal cell line 
3.1 Introduction 
Membrane proteins displaying elevated expression in tumour tissue relative to normal tissue have 
attracted considerable attention from cancer biologists recently as potential therapeutic targets or 
diagnostic markers. Unfortunately, membrane proteins are particularly difficult to separate in 2D gel 
systems and consequently other approaches, to profile the expression of membrane proteins, have 
been explored. 
The work reported in this section exploits the observation that most proteins on the cell surface are 
glycosylated by the post-translational linkage of carbohydrate moieties to specific amino acid residues 
(189). Protein glycosylation facilitates protein folding and stability, and plays an important role in cell 
adhesion and recognition process (189,190). Two categories of glycosylation have been identified: N-
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linked glycosylation and O-linked glycosylation (Fig 3.1). In N-linked glycosylation, the addition of 
carbohydrate moiety occurs at the amide nitrogen on the side chain of asparagine residues (Fig 
3.1a). In O-linked glycosylation, the addition of the carbohydrate moiety occurs on the hydroxyl 
oxygen on the side chain of hydroxylysine, hydroxyproline, serine, or threonine residues (Fig 3.1b)  
(189). 
In serine-and threonine -type O-linked glycoproteins, the carbohydrate moiety that is directly attached 
to the protein is GalNAc (N-acetylgalactosamine), whereas GlcNAc (N-acetylglucosamine) is directly 
linked to asparagine in N-linked glycoproteins. The carbohydrate chains in glycoproteins vary in 
length, composition and complexity (189,190). The carbohydrate chains typically include N-
acetylgalactosamine, N-acetylglucosamine, galactose, mannose, fucose, glucose, glucuronic acid, 
sialic acid and xylose. These can be organized in either simple, linear or complex, branched 
structures with O-linked glycoproteins less complex in comparison to N-linked glycoproteins 
(189,190). Protein glycosylation contributes extraordinary diversity to the chemical structure of 
proteins, thereby extending their functional role. 
 
 
 
 
 
Figure 3.1: Types of glycosylation (a) N-linked glycosylation: N-acetylglucosamine linked to 
asparagine (b) O-linked glycosylation: N-acetylgalactosamine linked to serine (figure adapted from 
(191) 
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Glycosyltransferases are responsible for catalyzing the addition of these carbohydrate moieties to 
proteins via an assembly line in the endoplasmic reticulum and Golgi compartment (189,190).  In 
contrast to glycoprotein assembly, the hydrolysis of glycoproteins occurs within lysosomes with 
various enzymes participating in the hydrolysis, depending on the complexity of the glycoprotein 
(189,190). Since most proteins on the cell surface are glycosylated, this provides an opportunity to 
target cell-surface proteins. The enzymatic reactions involved in the glycosylation and de-
glycosylation reaction have been exploited in the development of the proteomic approach utilized in 
this study (96). 
In this study, we targeted cell-surface glycoproteins with carbohydrate chains that terminate in 
galactose residues. Principally, the approach involves enzymatically replacing terminal galcatose 
residues with radio-labeled galactose, followed by the separation of membrane proteins on 
polyacrylamide gels. The enzyme used to hydrolyse the terminal galactose moiety in cell-surface 
glycoproteins is beta-galactosidase. Within the cell other substrates of beta-galactosidase include 
ganglioside GM1, lactosylceramides and lactose, but this method specifically targets cell-surface 
proteins (as described in Materials and Methods). 
The galactose moieties that were enzymatically removed are replaced by 3H or 14C – galactose, 
which are enzymatically added by galactosyltransferase (a glycosyltransferase specific for the 
addition of galactose moieties). The novelty of this approach resides on our ability to label cells from 
two different conditions (e.g. normal and cancer cells) with either 3H or 14
Although the method used in this chapter does not have the same resolving capacity as 2D-DIGE, it 
allows the separation of membrane proteins that are difficult to resolve in the IEF steps of 2D-DIGE. 
C – galactose, combining 
the samples followed by separation in the same lane by SDS-PAGE (as described in Materials and 
Methods).   
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Furthermore, the availability and access to this particular method encouraged the use of this method 
as opposed to more cutting-edge methods currently available. 
In this study, a labelling method exploiting de-glycosylation and glycosylation was used to determine 
altered protein expression in a cultured oesophageal cancer cell line in comparison to an 
immortalized normal cultured oesophageal cell line.  Proteins with altered expression in tumour cell 
lines compared to normal were identified and their expression status confirmed by 
immunohistochemistry in tissue sections. 
 
 
 
 
 
 
3.2 Materials and methods 
3.2.1 Propagation of cell lines 
Two cell lines, WHCO1 and EPC-2, were used in this section of the study. The WHCO1 cell line 
was derived from a squamous cell carcinoma of the oesophagus of moderate differentiation status, 
prepared at the University of Witwatersrand in South Africa and provided as a gift by Dr Rob Veale 
(University of Witwatersrand, South Africa). 
The EPC-2 cell line was developed from squamous epithelial cells, derived from the morphologically 
normal proximal oesophagus of a 55 year old male who underwent an oesophagectomy for Barret’s 
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oesophagus. The cell line was immortalized with telomerase  and provided as a gift by Prof A. Rustgi 
(University of Pennsylvania, Philadelphia, USA). 
WHCO1 cells were cultured and maintained in DMEM (Gibco-BRL, USA) containing 10% heat-
inactivated FBS (Gibco-BRL, USA), 100 units/ml penicillin and 100µg/ml streptomycin. EPC-2 cells 
were grown in KSFM (Gibco-BRL, USA) supplemented with 50µg/ml bovine pituitary extract (Gibco-
BRL, USA), 1ng/ml epidermal growth factor (Gibco-BRL, USA), 100 units/ml penicillin and 100µg/ml 
streptomycin. Both cell lines were incubated at 37ºC with 5% CO2
 
 humidity. On reaching 
confluency, the cells were rinsed and then removed from the substratum,  with 0.05% trypsin in PBS 
containing 10 mM EDTA, by incubation at 37ºC for 3-5 minutes. In the case of WHCO1 cells, 
trypsinisation was inhibited by the addition of an equal amount of DMEM containing 10% FBS. 
However, in the case of the EPC-2 cells, trypsinisation was inhibited by the addition of 0.25ng/ml 
Soya Bean Trypsin Inhibitor (Sigma, USA). The cells were pelleted by centrifugation at 500 X g for 5 
min, at 4°C (in a Beckman TJ-6), re-suspended in appropriate media and split at a ratio of 1:5 (to 
maintain cultures). 
 
3.2.2 Labeling of plasma membrane glycoproteins, plasma membrane protein 
preparation and protein separation 
Labelling of the plasma-membrane glycoproteins was performed according to a previously described 
method (96), with a few adaptations, courtesy of Dr Chris Maske (Division of Anatomical Pathology, 
University of Cape Town). 
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For each experiment, 0.5X106 cells were plated per 60 mm dish and incubated at 37ºC with 5% CO2
Once the media was aspirated, the cells were washed twice with ice-cold HEPES buffered saline. 
Cells were then treated with 100 µl of 0.2U/ml beta-galactosidase (prepared from Streptococcus 
pneumoniae and provided as a gift from Prof Lutz Thilo - Division of Medical Biochemistry, University 
of Cape Town) for 10 minutes at 4°C, to remove terminal galactose on the cell surface proteins. This 
was done by placing the 100µl beta-galactosidase in the centre of the dish and placing a 60mm disks 
over the surface of the plate, to spread the beta-galactosidase evenly across the dish, as illustrated 
(Fig. 3.2). The, disks had been cut from overhead transparency film (Pelikan, UK), and washed in 
0.1% detergent, rinsed twice in distilled water, rinsed with 70% ethanol and allowed to air-dry. After 
the 10 min β-galactosidase treatment, the disks were gently removed and the cells subsequently 
washed twice with ice-cold HEPES buffered saline, to remove the excess β-galactosidase. Cells 
were then labelled for 30 minutes at 4°C with a labelling/incubation mix (40µCi/ml UDP[6-
 
with humidity for up to 48 hours. Cells were subsequently placed on ice immediately prior to the 
labelling step and kept at 4°C for the duration of the experiment, in order to avoid membrane 
internalization.  
3H]GaI or 
UDP [U-14C]Gal, 0.5 U/ml Galactosyltransferase and 5mM MnCl) in the same manner as described 
for the β-galactosidase treatment and subsequently washed twice with ice-cold HEPES buffered 
saline. Cells were collected in 300 – 500 µl homogenisation buffer (containing a protease inhibitors 
cocktail – cOmplete, Roche) per dish, by scraping with a sterile rubber policeman and mechanically 
sheared by passing the collected cell suspension through a cell cracker. The post-nuclear 
supernatant (PNS) was prepared by centrifuging the cell homogenate at 1000 X g in a Beckman GS-
6R for 12 minutes at 4°C. A 20 µl aliquot of the PNS was placed in 3 ml scintillation fluid (Zinzer 
Analytic, UK) and counted in a Liquid Scintillation Analyzer 1900 CA (PACKARD, USA), to 
determine total dpm (disintegrations per minute) of labelled homogenate. This served as the first 
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checkpoint to determine if sufficient labelling had occurred. The experiment was terminated at this 
point if the total dpm of the labelled homogenate was less than 100 000 dpm.  
A layer of 0.5 ml 80% sucrose was deposited at the bottom of a Beckman Polyallomer centrifuge 
tube (14 X 95 mm), above which a layer of 27% Percoll was placed, as illustrated (Fig. 3.2). The 
PNS (approximately 2ml) was then slowly layered onto the 27% Percoll ® (Sigma, USA) gradient (as 
described in Appendix A) and the tube was centrifuged at 30 000 X g at 4 °C for 90 min in an SW-40 
rotor in a Beckman LM-8 ultra-centrifuge.  
After centrifugation, the sample was fractionated and 20µl aliquots, from each fraction, was placed in 
3ml scintillation fluid and counted in a Liquid Scintillation Analyzer 1900 CA (PACKARD, USA), to 
determine the amount of label in each fraction. Plasma membrane fractions corresponded to the 
fractions displaying peak dpm values. The fractions containing the plasma membrane fraction were 
collected, pooled and made up to 12 ml with ice-cold homogenisation buffer in a Beckman 
Polyallomer centrifuge tube (14 X 95 mm). The re-suspended membrane fraction was centrifuged at 
130 000 X g for 2 hours at 4°C in an SW-40 rotor in a Beckman LM-8 ultra-centrifuge to pellet the 
membranes. The supernatant was discarded and the pellet was re-suspended in 2.5 ml 0.5M KCl 
and transferred to a thick-walled Beckman tube.  The samples were sonicated 12 times for 5 
seconds, whilst on ice. Sonication allowed the disruption of membranes that formed micelles, 
facilitating the release of the content of the micelles, thereby allowing the purification of membranous 
particulate only. The samples were then centrifuged at 70 000 X g at 4°C for 1 hour in a Beckman 
70.1 Ti rotor in a Beckman LM-8 ultra-centrifuge to pellet the membrane fraction. The opaque 
membrane pellet was collected and the label quantitated by counting a series of aliquots (2µl, 4µl 
and 8µl) in a liquid scintillation analyzer. These values were used to calculate the yield of 
radioactively labelled membranes. 
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Figure 3.2: Labelling method: Flow diagram describing method of labelling plasma-membrane 
glycoproteins. (1) Remove media and wash twice with Hepes saline (2) Place 100 μl Beta 
galactosidase in centre of dish and gently overlay transparency disk to spread (3). After 10 min 
remove disk and wash twice with Hepes saline (4)Place 100 μl labelling mix (containing 3H 
and 14
One part 
C) in centre of dish and gently overlay transparency disk to spread (5) After 30 min remove 
disk and wash twice with Hepes saline (6) Scrape cells with rubber policeman in up to 500μl 
homogenisation buffer and transfer all cells to a 12 ml tube (7) Mechanically shear cells with a 
cell cracker (8) Prepare PNS via centrifugation (500 X g for 12 minutes) (9) Apply PNS to 
27%Percoll gradient (10) Centrifuge at  30 000 X g for 90 min at 4°C (11) Fractionate via 
mechanical fractionation (12) Pool fractions corresponding to radioactively labelled plasma 
membrane with homogenization buffer (13) Centrifuge at 130 000 X g for 2hours at 4°C (14) 
Collect opaque pellet, re-suspend in 0.5M KCl and sonicate (15) Centrifuge at 70 000 X g for 1 
hour at 4°C to reveal the membrane pellet. 
14C-labelled proteins were mixed with 4 parts 3
Pellet of cell debris
Count 20μl PNS for labelling
efficiency 
PNS
Cells and media on ice
1. Wash twice
2. Add Beta galactosidase
3. Wash twice
4. Add labelling mix
5. Wash twice
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12 ml tube
7. Break cells
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H-labelled proteins, re-suspended in loading 
buffer (see Appendix A) and separated on a gradient of 8% to 15% by SDS-PAGE (Fig 3.3 - lane 3) 
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(details in Appendix A).  14C-labelled proteins were always loaded in excess to 3H-labelled proteins in 
lane 3, as the energy emission spectra for 14C and 3H overlap. During subsequent dual counting of 
these radio-isotopes (via liquid scintillation counting), the 14C energy emission that overlaps into 
the 3H energy emission window is not included in 3H counts. However, due to the overlap in energy 
emission spectra more 3H label needs to be included to raise 3H energy emission above 
background 14
 
C energy emission.    
 
 
 
               
 
 
Lane            1                2                        3 
Figure 3.3: Sample Loading: Scheme illustrating sample loading for 14C and 3H- labelled membrane 
protein fraction. Lane 1: Molecular-weight marker, Lane 2: Two parts 14C-labeled protein and Lane 3: 
Mixture of one part 14C and four parts 3
 
H- labelled membrane protein. The vertical red line in Lane 2 
indicates that the lane was cut into two parts and used for counting and MS analysis, respectively. 
A molecular-weight marker was loaded in lane 1, and 2 parts 14C-labelled protein was loaded in lane 
2, for subsequent identification and analysis (Fig 3.3). 14C-labelled proteins from half of lane 2 were 
used as an internal control. 14C- labelled proteins from lane 2 should have approximately double the 
value of 14C-labelled proteins in lane 3. Therefore 14C- labelled proteins from half of lane 2 should 
have similar values compared to 14C-labelled proteins in lane 3, assuming co-migration of proteins in 
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lanes 2 and 3 in the poly-acrylamide gel.  In principle, this step provides a mechanism to check that 
the proteins in the gel slice of interest in lane 3 correspond to the same proteins in the gel slice in 
lane 2.  
3.2.3 Post-staining, gel anlysis, slice excision and digestion 
Gels were stained with Coomassie Blue; typically, gels were stained and fixed in coomassie blue 
staining solution for 12 minutes and subsequently de-stained overnight. The following steps were 
performed with gloves in a sterile area, free of contaminating proteins. All utensils and surface areas 
were washed with detergent and sprayed down with 70% ethanol. Gels were dried and a grid with 
slices 0.5 mm in height and 1.5 cm wide was drawn on the gel in order to excise slices for further 
analysis.  
Half of the gel slices in lane 2 (indicated by the red line in Fig. 3.3) and the gel slices from lane 3 
were subsequently processed as follows (Fig. 3.4). The proteins in the excised slices from the 
stained gel were in-gel digested in 1.5 ml Eppendorf tubes, with 1 ml trypsin-EDTA, pH 7.4 at 37°C 
overnight. The extracted peptides from the first round of extraction in the 1 ml trypsin was transferred 
to a scintillation vial with 3 ml scintillation fluid and stored O/N in the dark at room temperature. 
Another 1 ml trypsin-EDTA was added to the remaining gel slice O/N at 37°C, for a second round of 
peptide extraction (Fig. 3.4). The second round of extracted peptides in the 1 ml trypsin was added to 
the scintillation vial as from the first round. Label was measured on a dual counting protocol on the 
liquid scintillation analyzer, to separately give the dpm for each isotope as an indication of amount of 
labelled peptides of each type. In each O/N extraction, care was taken to ensure that no gel slice 
residue was transferred to the scintillation fluid.  
The data obtained were normalized and represented graphically (Graphpad Prism version 5 and 
Microsoft Excel Software ©). The data were plotted as a profile of radioactivity against the slice 
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number. For direct comparison of two profiles (3H or 14
 
C), the relative areas under each profile were 
normalized to the same/similar values.                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Gel trypsinisation: Scheme illustrating procedure for trypsinisation of gel slices, to release 
radioactively labelled peptides for counting in a liquid scintillation analyzer. 
 
Marker  Slice number  Lane 2                       Lane 3
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Gel slice from half of Gel slice from
Lane 2 Lane 3
Count in scintillation counter
ROUND 1
Plus 1 ml Trypsin at 37°C O/N
Gel slice from half of lane 2 
with ROUND 1 trypsin
Gel slice from lane 3 with 
ROUND 1 trypsin
Transfer trypsin from ROUND 
1 to scintillation tube tube
Gel slice from half of lane 2 
with ROUND 2 trypsin
Gel slice from lane 3 
with ROUND 2 trypsin
ROUND 2
Plus 1 ml Trypsin at 37°C O/N
Transfer trypsin from ROUND 2 
to scintillation tube tube
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In order to observe differences in protein expression in tumour compared to normal cells, ratios of the 
two labels in each slice were calculated and compared. 
Slices that displayed reproducible differences between all three experiments were further 
investigated. Slices of interest from lane 3 were targeted for further investigation and the 
corresponding gel slice from the remaining half of lane 2 was sent for identification. 
3.2.4 ESI-QUAD-TOF MS and identification of proteins 
Gel slices from lane 2 were stored at RT, until further use. Digested peptide extracts were subjected 
to electron-spray ionisation linked to a quadrupole-time-of-flight mass analyser (ESI-QUAD-TOF). 
Proteins were subsequently identified using Mascot Daemon (Matrix Science, UK). Identifications 
were accepted when percentage protein coverage exceeded 25% and MOWSE scores were higher 
than the threshold value (P=0.05), the predicted protein mass agreed with the gel-based mass and 
the proteins identified were human. Once proteins were identified, the expression levels of the protein 
in tumour tissue were compared to normal tissue using immunohistochemical staining on tissue 
sections. 
3.2.5 Confirmation of protein expression by IHC 
Frozen sections of tumour and normal tissue from 10 oesophageal cancer patients were used. 
Sections were blocked for endogenous peroxidase activity by submerging the slides in 3% hydrogen 
peroxide for 20 minutes. The slides were then incubated at room temperature with a 1/20 dilution of 
goat serum (Dako, California) for 30 minutes. The mouse antibody to CD98 (heavy chain) (C2443-81, 
Unites States Biological)   was used at a dilution of 1/250 for 1 hr at RT. The omission of the primary 
antibody served as a negative control in each case. The Envision-polyallomer detection system 
(DAKO, California) was used according to manufacturer’s instructions to visualise the location of the 
antibody.  Sections were visualized by staining with DAB chromagen as previously described in 
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Chapter 2. Sections were counterstained with haemotoxylin and subsequently dehydrated. The slides 
were independently evaluated by a qualified anatomical pathologist.  
The criteria used to score IHC staining are outlined in Table 3.1. CD98 is expressed on the plasma 
membrane and therefore membrane staining in cells was evaluated when scoring IHC staining.  
 
Table 3.1: Criteria used by independent pathologist for scoring IHC slides. Slides were assigned a 
score of 0 to 4+ based on the percentage membrane staining observed in a tissue section. 
Intensity 
Percentage membrane staining in field of 
view 
0 less than 5% stained 
1+ between 5 and 25% stained 
2+ between 26 and 50% stained 
3+ between 51 and 75% stained 
4+ more than 75% stained 
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3.3 Results 
3.3.1 Radioactive labeling of plasma membrane glycoproteins 
Checkpoints were included at various steps in the radioactive labelling method in order to determine 
the efficiency of the labelling procedure. Essentially, aliquots were taken at these checkpoints for 
measuring labelling efficiency. The results that follow are representative of 3 experiments performed, 
but only the details of one are presented here. 
The first checkpoint was taken subsequent to preparing the PNS. On average the total counts in the 
PNS exceeded 100 000 dpm for both 3H and 14C labelling. Counts above this threshold indicated that 
there was sufficient labelling to continue with the experiment. In all cases labelling efficiency was 
higher in WHCO1 cell lines (14C labelled) compared to EPC-2 hTERT (3
Once the PNS was fractionated, the bulk of the label was concentrated in the fraction, which 
contained the membrane proteins (Fig. 3.5). The elution profile of the labelled protein reflected the 
volume of the PNS loaded on the Percoll gradient. Fractions 14 to 18 (from 
H labelled). The total dpm of 
the PNS from each were 845 716 dpm and 532 800 dpm, respectively.  
14C labelled proteins) and 
fractions 12 to 18 (from the 3
Subsequent to washing, aliquots of the purified plasma membrane protein preparation were counted 
on a liquid scintillation analyzer, in order to calculate the amount of radioactively labelled proteins in 
the sample. For efficient analysis by SDS-PAGE, the protein samples had to fulfil two criteria. First, 
the intensity of labelling should be sufficient so that more than about 3000 dpm could be loaded on a 
lane. This was required so that sufficient counting accuracy was obtained. Second, at least 4-fold 
H labelled proteins) (Fig. 3.5) were pooled and membrane proteins were 
collected by centrifugation, followed by washing proteins as described in Materials and Methods.  Un
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more radioactivity must be loaded for the 3H-labelled samples, in order to minimise the effects of 14C-
spillover with the 3
 
H counting channel during dual isotope scintillation counting.  
 
 
 
 
 
Figure 3.5:  Elution profile of labelled PNS after density centrifugation on a 27% Percoll gradient. 
PNS’s were prepared from WHCO1 cells (14C, total   845 716 dpm  ) and from EPC-2 cells (3
 
H, 
total 532 800 dpm  ). Fractions that contained labelled membrane proteins (indicated by the 
red brackets) were collected for further analysis) 
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Figure 3.6:  Data representative of method used to calculate concentration of radioactively labelled 
sample:  Aliquots of 2, 4 and 8µl were counted on a liquid scintillation analyzer and the corresponding 
dpm plotted, as shown. The concentration of label (dpm/µl) was obtained from the slope of a linear 
regression line. 3H-labelled protein profile in blue ( ) and the 14
The data presented here are indicative of a typical labelling efficiency (Fig. 3.6). The concentration 
calculated for the 
C- labelled profile in pink ( ).  
14C-labeled protein sample is 623.82 dpm/µl and the concentration for 3
3.3.2 Profile pattern of proteins showing altered levels of expression 
H-labelled 
protein sample is 84.64 dpm/µl (Fig. 3.6). Concentrations of samples were calculated as described in 
Materials and Methods.  
Separation of proteins on large format 1-dimensional SDS polyacrylamide gels allowed the excision 
of 60-100 slices per lane. As described in Materials and Methods, these slices were trypsinized and 
the radioactivity of eluted peptides were quantitated by scintillation counting.  
Representative data are summarized in Table 3.2. In this experiment, the sum of the dpm of 3H-
labelled proteins from lane 3 (as in Fig 3.3) was 6152.31 dpm, the sum of the dpm of 14C-labelled 
proteins from lane 2 (as in Fig. 3.3) was 6609.9 dpm and the sum of the dpm of 14
Figure 3.7 is a representative image of 3 independent experiments. Different levels of expression in 
the tumour cell line compared to the normal cell line, were observed (Top panel in Fig.3.7). The four 
slices corresponding to slices 15, 17, 24 and 27, highlighted as pink, blue, orange and green 
respective bands running vertically through the graph (Fig 3.7), were reproducibly found to display 
elevated levels in the tumour cell line compared to the normal cell line. Furthermore, the average 
C-labelled proteins 
from lane 3 (as in Fig. 3.3) was 4975.31 dpm. For a direct comparison of the radioactivity profiles, 
the areas under the curve were normalised to the same value, as outlined in Materials and Methods 
(Table 3.2). Normalized dpm values were then plotted versus slice number, to yield data as 
represented in Figure 3.7. 
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ratios of peptides from these gel slices displayed at least 1.5–fold increased levels in tumour 
compared to normal cells (Table 3.3). 
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Figure 3.7: Radioactive profiles: Radioactive profile of glycosylated proteins on the surface of 
WHCO1 cells, labelled with 14C, and glycosylated proteins on the surface of EPC-2 cells, labelled 
with 3H. The top panel displays the 3H-labelled protein profile in blue ( ) and the 14C- labelled 
profile in pink ( ) from the lane in which the labelled samples were mixed (Lane 3 in Figure 3.3). 
The middle panel shows half of the lane (Lane 2 in Figure 3.3) containing 14C-labelled protein only 
(used to identify proteins of interest via ESI-QUAD-TOF-MS). The other half of this lane (Lane 2 in 
Figure 3.3) was prepared (as described in Materials and Methods) to yield the profile of 14C-labelled 
proteins (        ), as seen in the bottom panel, in comparison to the 14
           
 
 
  
C-labelled proteins from the lane 
in which the labelled samples were mixed (Lane 3 in Figure 3.3). The brown lines indicate the 
position of the molecular weight markers. The pink (slice 15), blue (slice 17), orange (slice 24) and 
green (slice 27) elongated boxes across the image highlight the proteins of interest that were picked 
and sent for identification via ESI-QUAD-TOF-MS analysis. 
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Slice number
14C counts 
from lane 
3 (dpm)
3H counts 
from lane 
3 (dpm)
14C counts 
from lane 
2 (dpm)
14C counts 
from lane 
3 (dpm) 
normalized 
to 3H 
counts in 
lane 3
14C counts 
from lane 3 
(dpm) 
normalized 
to 14C 
counts lane 
2
1 205.0867 295.03 205.4 254.30747 272.76527
2 250.7 305.8867 238.37 310.868 333.431
3 208.16 211.37 231.95 258.1184 276.8528
4 138.46 153.9633 177.66 171.6904 184.1518
5 104.28 139.2 158.06 129.3072 138.6924
6 104.8933 159.31 153.52 130.06773 139.50813
7 85.56333 137.6767 129.33 106.09853 113.79923
8 106.4867 156.6933 130.13 132.04347 141.62727
9 83.45 117.9833 150.59 103.478 110.9885
10 131.9033 201.5233 217.78 163.56013 175.43143
11 262.75 353.86 331.28 325.81 349.4575
12 234.9833 307.7367 342.54 291.37933 312.52783
13 138.91 147.5367 247.03 172.2484 184.7503
14 151.3133 132.7667 231.76 187.62853 201.24673
15 195.9733 156.6467 255.11 243.00693 260.64453
16 185.4267 149.2333 277 229.92907 246.61747
17 292.87 202.6433 341 363.1588 389.5171
18 263.19 221.6233 297.75 326.3556 350.0427
19 187.5733 184.5267 296.69 232.59093 249.47253
20 146.6633 158.76 172.38 181.86253 195.06223
21 81.83 103.79 107.64 101.4692 108.8339
22 84.66 104.9167 116.38 104.9784 112.5978
23 68.16 75.15667 87.66 84.5184 90.6528
24 81.98 70.25 109 101.6552 109.0334
25 85.42 82.16 108.24 105.9208 113.6086
26 76.98 71.89 109.7 95.4552 102.3834
27 104.3867 76.77667 129.67 129.43947 138.83427
28 92.4 83.51667 130.71 114.576 122.892
29 69.43333 68.75667 94.99 86.097333 92.346333
30 69.24667 72.39 113.22 85.865867 92.098067
31 58.52333 64.77667 88.92 72.568933 77.836033
32 61.41333 73.98667 86.28 76.152533 81.679733
33 57.63 75.61667 73.36 71.4612 76.6479
34 46.13333 84.7 57.11 57.205333 61.357333
35 56.57 85.95667 43.61 70.1468 75.2381
36 43.76 95.4 56.01 54.2624 58.2008
37 32.31333 67.53333 39.88 40.068533 42.976733
38 24.76333 51.5 27.94 30.706533 32.935233
39 20.42 43.55 26.99 25.3208 27.1586
40 19.50667 42.47 22.59 24.188267 25.943867
41 18.92667 49.66 22.82 23.469067 25.172467
42 24.45667 53.49 20.88 30.326267 32.527367
43 11.66667 33.64333 18.86 14.466667 15.516667
44 17.73667 47.22 14.71 21.993467 23.589767
45 15.43667 40.50667 15.06 19.141467 20.530767
46 13.22667 37.97 15.86 16.401067 17.591467
47 11.73333 33.95667 16.46 14.549333 15.605333
48 10.20667 30.5 15.37 12.656267 13.574867
49 11.16333 25.56667 12.92 13.842533 14.847233
50 9.23 30.7 14.26 11.4452 12.2759
51 8.4 21.67333 16.31 10.416 11.172
52 6.556667 23.98333 15.12 8.1302667 8.7203667
53 9.25 27.58 13.13 11.47 12.3025
54 9.193333 21.46667 15.05 11.399733 12.227133
55 10.21 20.39333 16.09 12.6604 13.5793
56 9.603333 23.46 15.55 11.908133 12.772433
57 8.12 20.05667 14.41 10.0688 10.7996
58 9.213333 22.46667 18.09 11.424533 12.253733
59 8.65 19.49333 15.36 10.726 11.5045
60 5.536667 17.44333 14.86 6.8654667 7.3637667
61 5.996667 20.66667 9.11 7.4358667 7.9755667
62 7.093333 38.94667 12.85 8.7957333 9.4341333
63 3.403333 19.79333 10.01 4.2201333 4.5264333
64 3.253333 21.51 8.1 4.0341333 4.3269333
65 4.596667 16.52667 9.44 5.6998667 6.1135667
66 2.283333 17.84667 7.16 2.8313333 3.0368333
67 3.966667 12.38667 9.3 4.9186667 5.2756667
68 2.033333 14.34 7.53 2.5213333 2.7043333
Sum of 
counts (dpm) 
or area under 
the curve 4975.31 6152.31 6609.9 6169.3844 6617.1623
Original values Normalized values
 
Table 3.2: Data of counts obtained for gel slices   
containing radiolabeled proteins (dpm): In this experime  
68 slices (0.5 mm X 1.5 cm) were excised from lanes          
2 and 3 (see Fig. 3.4). Gel slices were trypsinized and 
peptides eluted, as described. Radioactivity of eluted 
peptides were counted on a liquid scintillation counter. 
Counts were normalized to give the same area under      
radioactivity profile, as described in Materials and Metho  
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The matched gel slices from lane 2 were subsequently digested and subjected to ESI-QUAD-TOF 
MS for identification. 
3.3.3 Identification of proteins 
Staining of gels revealed that protein levels were too low for Coomassie Blue detection and possibly, 
for successful MS-based identification. Of the four slices subjected to ESI-QUAD-TOF-MS analysis, 
only one slice was successfully identified (Gel slice 17 in Fig. 3.7 and ).  
The scoring system used here is based on the MOWSE scoring algorithm (used in Mascot 
searches). Probability-based MOWSE scores for peptides obtained from gel slices 15, 24 and 27 
indicated that no significant hits were identified (Fig. 3.8 a, c and d). The probability-based MOWSE 
scores obtained for peptides from gel slice 17 indicated a number of hits that exceeded the 
significance threshold (p< 0.05) (Fig. 3.8 c and f). Although the percentage coverage of the protein 
identified is only 12% (lower than the limits outlined in Materials and Methods i.e. 25%), the 
probability that this identification is correct is significantly high, as the top 10 significant hits indicate 
the same protein (i.e. member of the solute carrier 3 protein family) with varying percentage protein 
coverage (Fig. 3.8 e and f). 
The protein identified is a member of the solute carrier 3 protein family of amino acid transporters and 
will be referred to as CD98 hc from this point. According to its location on the gel, it corresponds to 
approximately 85 kDa (Fig. 3.8). However, bioinformatics search engines predict its molecular weight 
at approximately 57.9 kDa, (accession number: P08195). However, the predicted mass generated by 
the search engines does not take into account glycosylation status, which would affect the 
electrophoretic mobility of this protein in an SDS-PAGE gel. Reports in the literature confirm that the 
molecular mass, based on SDS-PAGE analysis of CD98 hc, is indeed approximately 80kDa (192). 
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Figure 3.8: Images reproduced from Mascot search results (www.matrixscience.com): (a), (b), (c) 
and (d) indicate probability based MOWSE score for gel slices 15, 17, 24 and 27, respectively. Each 
red bar indicates a hit observed for the peptide of interest, however, only red bars NOT in green 
shaded areas are considered significant as in (b) where the probability-based MOWSE score for gel 
slice 17 indicates that all scores above 70 are significant (p< 0.05). Score is -10*Log(P), where P is 
the probability that the observed match is a random event. (e) The green box highlights the top 10 
significant protein identifications that displayed the highest score for peptides from gel slice 17. The 
red box outlines the most significant hit as being a member of solute carrier family 3 and  (f) displays 
amino acid sequence of solute carrier 3 protein where red highlighted amino acids are those that 
matched amino acid sequences from peptides obtained from gel slice 17, amounting to a 12% 
protein coverage.   
 
 
 
 
1 MSQDTEVDMK EVELNELEPE KQPMNAASGA AMSLAGAEKN GLVKIKVAED 
51 EAEAAAAAKF TGLSKEELLK VAGSPGWVRT RWALLLLFWL GWLGMLAGLK 
101 GRLDYLSSLK VKGLVLGPIH KNQKDDVAQT DLLQIDPNFG SKEDFDSLLQ 
151 SAKKKSIRVI LDLTPNYRGE NSWFSTQVDT VATKVKDALE FWLQAGVDGF 
201 QVRDIENLKD ASSFLAEWQN ITKGFSEDRL LIAGTNSSDL QQILSLLESN 
251 KDLLLTSSYL SDSGSTGEHT KSLVTQYLNA TGNHWCSWSL SQARLLTSFL 
301 PAQLLRLYQL MLFTLPGTPV FSYGDEIGLD AAALPGQPME APVMLWDESS 
351 FPDIPGAVSA NMTVKGQSED PGSLLSLFRR LSDQRSKERS LLHGDFHAFS 
401 AGPGLFSYIR HWDQNERFLV VLNFGDVGLS AGLQASDLPA SASLPAKADL 
451 LLSTQPGREE GSPLELERLK LEPHEGLLLR FPYAA 
a c
b d
f
e
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 Table 3.3: Results of proteins sent for identification: Av. Ratio = Average ratio: indicates fold-
difference of the protein in tumour cells compared to normal cells, IPI number = International protein 
index reference number, pI = pH at which protein’s charge is zero according to protein database, Mw 
(pred) Da = Molecular weight in Daltons according to protein database, Mw (gel) Da = Molecular 
weight in Daltons according to observed migration, Score = Number of peptides matching the top hit 
from Mascot Daemon programme versus the total number of masses submitted, % Cov = Amino 
acid sequence coverage for the identified protein 
 
The identification of the peptides from gel slice b to match CD98/SLC3A2 with a score of 91 
exceeded the threshold for significance (70). In order to validate the expression of CD98 hc, by an 
alternative independent method, IHC was applied. 
3.3.4 Confirmation of protein expression by IHC 
IHC staining of frozen tissue was used to assess the expression of CD98 hc in oesophageal tumours 
and paired normal tissues from 10 patients. In normal epithelia, the basal cells (or less differentiated 
tissue) stained exclusively in comparison to the rest of the tissue (Fig. 3.9a and b). The staining was 
confined to the plasma membrane. The upper or more differentiated layers in normal epithelia stained 
very weakly. Due to the type of staining pattern observed in the normal epithelia, scoring the level of 
staining could not be executed. 
Gel   
slice 
    Av. Ratio 
(Tumour/Normal) 
           Name  IPI  number pI (pred) Mw (pred)  
    Da 
Mw (gel) 
    Da 
Score %Cov 
  15        1.7     No significant hits See Fig. 3.9 a 
  17        1.5 solute carrier family 3,     
CD98 hc, 4F2 heavy    
chain, MDU1 
IPI00027493    4.93   57944  85 000 91 12% 
  24        1.5     No significant hits See Fig. 3.9 b 
  27        1.9     No significant hits See Fig. 3.9 c 
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Scoring criteria was successfully applied to the corresponding tumour tissue for all 10 patients (Table 
3.4). Of the patient tissue evaluated, 90% of tumour tissue displayed more than 75% staining of 
CD98 hc (Table 3.4 and Fig. 3.9 c-f). An intense staining pattern was observed for CD98 hc as early 
as dysplasia (Fig. 3.9 c and d).  
Table 3.4: IHC staining score for patient cohort: Observations are based on percentage membrane 
staining in tissue section. T indicates tumour section. Scoring for normal tissue was not included as 
basal cells stained exclusively in comparison to rest of the tissue. Scoring criteria: 0 indicates less 
than 5% stained, 1+ indicates between 5 and 25% stained, 2+ indicates between 26 and 50% 
stained, 3+ indicates between 51 and 75% stained and 4+ indicates more than 75% stained. 
 
 
 
 
 
 
 
 
4+10
4+9
4+8
2+7
4+6
4+5
4+4
4+3
4+2
4+1
TPatient number
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Figure 3.9 : Immunohistochemical staining of CD98 hc: (a) and (b) indicates weak membrane 
staining of in normal epithelia in suprabasal layers and intense staining in the basal layer where (a) is 
[40X] and (b) is [100X], (c) and (d) indicates strong membrane staining in dysplastic epithelia where 
(c) is [40X] and (d) is [100X], (e) and (f) displays intense staining in invasive carcinoma but not in 
stroma where (e) is [40X] and (f) is [100X]. [ ] indicates strength of magnification, L indicates Lumen, 
E indicates epithelia,             indicates Basal cells and S indicates Stroma. 
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Although normal epithelial staining for CD98 hc could not be scored because staining was confined 
to basal and suprabasal cells, CD98 hc expression was markedly elevated in tumour tissue 
compared to normal tissue (Fig. 3.9 a, b, e and f) in all 10 sections examined, confirming the results 
observed by REQUA linked to ESI-QUAD-TOF-MS analysis.  Furthermore, the plasma membrane of 
dysplastic epithelial cells (Fig. 3.9 c and d) stained strongly for CD98 hc, relative to the weak CD98 
staining observed in the maturing cells from the normal epithelia (Fig. 3.9 a-d). The enhanced 
expression of CD98 hc in dysplasia earmarks CD98 hc expression as a possible early diagnostic 
marker for the development of OSCC. 
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3.4 Discussion 
REQUA (relative quantification of glycosylated proteins) offers the opportunity to decrease the 
complexity of a sample, by allowing the analysis of a subset of proteins on the surface of cells. This 
method was previously used to aid in the molecular characterisation and interactions of phagosomes 
in Mycobacterium tuberculosis and Mycobacterium avium (193,194). We report the first use of 
REQUA to identify glycosylated surface proteins that display altered expression in tumour cells 
compared to normal cells. 
The type of cell line used makes a significant impact on labelling efficiencies of the method used. 
Cells of Dictyostelium discoideum showed a high labelling efficiency (96,97),  in contrast to the cells 
used in this study that displayed a relatively low labelling efficiency, despite the use of same labelling 
parameters. The low percentage of labelling observed in this study could be due to the losses 
incurred in the extensive washing steps, required to yield a plasma membrane protein preparation, or 
the number of cells used during labelling.  
Because REQUA allows reduction in sample complexity, it is possible to avoid using iso-electric 
focusing as a primary separation approach followed by SDS-PAGE. Hydrophobic proteins are 
notorious for not separating well during iso-electric focusing, therefore affecting the ability of 2D gel 
electrophoresis to identify proteins of a hydrophobic nature. REQUA does not include an iso-electric 
focusing step, thereby allowing the identification of hydrophobic proteins on the surface of the cell.  
REQUA, however, like most proteomic methods does have its drawbacks. The method is time 
consuming and some of the reagents are relatively expensive. Furthermore, REQUA can only be 
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applied to cells in culture. Like all other proteomic methods, the levels of proteins of interest must be 
validated using an alternative method, such as IHC. REQUA is also unfortunately not ideal for use as 
a high-throughput method. Although REQUA has previously been used successfully (193) to identify 
a number of glycosylated proteins, in this study we were only able to identify one of the four 
membrane bound glycosylated proteins of interest. The reason for the low rate of identification is 
related to the amount of protein available in each slice. The use of radioactivity allows for increased 
sensitivity, thereby allowing the identification of proteins displaying altered expression. Unfortunately, 
the amount of radioactivity does not necessarily translate to the quantity of protein in the slice of 
interest, considering multiple proteins would be in present in one gel slice. Furthermore, we also 
observed degradation of proteins that were stored. MALDI-MS analysis was performed in Germany. 
Possibly the long-term storage of samples (prior to analysis) led to degradation of proteins thereby 
translating to a low extraction yield from the gel slice of interest.  
The protein identified was CD98 heavy chain (hc). CD98hc is an 80 kDA transmembrane protein, 
with the C-terminus presenting outside the cell. CD98 hc is also known as 4F2, Lymphocyte 
activation antigen 4F2 large subunit, MDU1 and NACAE (195). CD98 hc is part of the solute carrier 3 
protein family and is commonly referred to as SLC3A2 (195). The glycosylated CD98 hc forms part 
of a heterodimer with the non-glycosylated CD98 light chains 1, 2 and 3 (LAT-1: L-amino acid 
transporters) to form the CD98 protein or Heteromeric Amino acid Transporter (HAT) complex that 
represents several of the classical mammalian amino acid transporters (196,197). Haynes et al first 
characterised CD98 protein in 1981 as a T-cell activation antigen comprising of an 80kDa heavy 
chain and a 40 kDa light chain (192,198). Later it was determined that CD98 protein is responsible 
for the transport of neutral amino acids (199). However, CD98 protein has also been shown to play a 
role in cell fusion, cell adhesion, cell survival, integrin and adhesive signalling and cell proliferation 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  88 
(200-207), although the exact mechanism by which CD98 hc contributes these processes is not 
known (208-210).                   
An increase in cell proliferation is associated with an increase in metabolic requirements, reflected by 
the increased level of CD98 hc observed in both the basal and suprabasal cells of normal epithelia 
and the increased expression in tumour tissue (211). For growth, proliferation and maintenance of the 
tumour cells, protein biosynthesis is required and therefore transport of amino acids (from outside of 
the cells to inside of the cells) becomes important. 
Increased levels of CD98 hc have been observed in  other cancers, such as breast cancer, ovarian 
cancer and gliomas (212-214). In this study, we observed a marked increased of CD98 hc levels in 
oesophageal cancer tissue compared to normal tissue. The involvement of CD98 hc in proliferation 
suggests that this protein may be a good target for cancer therapy. However, it is ubiquitously 
expressed in all tissues with high levels in certain tissues such as the kidney, placenta and testis 
(197,215). Despite the ubiquitous expression of this protein,  a humanized antibody to CD98hc has 
been developed and is currently being investigated as a potential means of therapeutic intervention 
(216). Furthermore, CD98 hc has been patented as an early diagnostic marker for cancer (215).  
In addition to the potential of CD98 hc as a means of therapeutic intervention, Xiao et al (217) 
demonstrated reduced levels of CD98 in the plasma of individuals with lung cancer. CD98 levels in 
plasma have been included in a panel with other proteins to have good predictive value in lung 
cancer staging, with a high degree of specificity and sensitivity. The study by Xiao et al (217) 
suggests that CD98 can be included in a cohort of proteins to serve as a prognostic marker for lung 
cancer.  
Although our study did not explore whether CD98 hc is shed into the extracellular milieu of 
oesophageal tissue, our study does highlight CD98 hc as a potential prognostic marker for early 
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diagnosis of OSCC. Furthermore, based on developments in the literature regarding the humanizing 
of CD98 hc antibodies, it is conceivable that CD98 hc could be a credible target for treatment of 
OSCC in the future. 
 
 
 
 
4 DCA as a potential therapeutic drug in OSCC 
4.1 Introduction 
Comparative 2D-DIGE analysis of proteins from tumour and normal tissue from OSCC patients 
showed elevated levels of glycolytic enzymes in tumour tissue compared to normal tissue. 
Subsequent immunohistochemical analysis of paraffin-embedded tissue confirmed that levels of 
glycolytic enzymes (PK and GPDH) were indeed elevated in OSCC patients (Fig. 2.10).  
The increase in glycolytic enzymes in tumour cells compared to normal cells, reflecting an increased 
dependence of tumour cells on glycolysis as an energy source, is a well-described phenomenon, 
referred to as the Warburg effect.  Otto Warburg first described this phenomenon in the late 1920’s 
and since then it has been recognised as a phenomenon typifying cancer cells (131). In cancer cells, 
elevated levels of glycolytic enzymes occur since glycolysis is utilised as the primary source of ATP 
production, despite the availability of oxygen. It is thought that this increase in aerobic glycolysis is 
due to mitochondrial dysfunction, conferring apoptotic resistance, as a result of increased 
mitochondrial membrane potential.  The latter increase in membrane potential has been reported in 
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many cancers and it has been shown that decreasing membrane potential, results in the induction of 
apoptosis (139,218,219).  
Targeting cells displaying increased glycolytic pathway activity therefore represents a novel means of 
therapeutic intervention. A recent publication by Bonnet et al, describes the use of dichloro acetic 
acid (DCA) as a potential therapeutic agent for glioblastoma cells, which also displayed elevated 
glycolytic pathway activity (139).  DCA can shift cellular metabolism from primarily glycolysis to 
include the Kreb’s cycle and oxidative phosphorylation as key energy sources. DCA inhibits pyruvate 
dehydrogenase kinase (PDK), which in turn inhibits pyruvate dehydrogenase (PDH) (Fig. 4.1) (220).  
PDH controls the link between glycolysis and the Krebs cycle, if PDH is inhibited, pyruvate is not 
shuttled to the Krebs cycle, which results in reduced levels of oxidative phosphorylation (220,221).  
DCA allows PDH to remain activated, by inhibiting PDK, and in so doing enables oxidative 
phosphorylation to take place with the associated generation of reactive oxygen species (ROS). ROS 
generation leads to decreased mitochondrial membrane potential, resulting in the generation of 
apoptotic inducing factors (Fig. 4.1.), which would normally facilitate the induction of apoptosis in 
stressed cells. In cancer cells, this ability to induce apoptosis in response to abnormal stress is by-
passed (139,222).  
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Figure 4.1: Schematic diagram illustrating mechanism by which DCA triggers apoptosis in tumour 
cells (adapted from (139)). 
 
The significance of Bonnet’s study is, however, that DCA only affects tumour cells and not normal 
cells, by targeting the glycolytic pathway. DCA treatment exploits the inability of tumour cells to 
commit pyruvate to the metabolic processes in mitochondria, whereas normal cells display normal 
mitochondrial activity and are not susceptible to DCA treatment (139,220). Others have subsequently 
shown that by targeting the glycolytic pathway with DCA,  in cultured cells, apoptosis is induced in 
cancer cells with no effect on normal cells (218). In this chapter we investigated whether targeting 
the glycolytic pathway of OSCC cells, with DCA, would be an effective therapeutic treatment in 
OSCC, using cell culture as a model system. 
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4.2 Materials and Methods 
4.2.1 Propagation of cell lines 
The cell lines used included WHCO1 (obtained as a gift from Dr R. Veale, University of 
Witwatersrand, South Africa), KYSE 30 and KYSE 450 (obtained as a gift from Prof Y. Shimada, 
Kyoto University, Kyoto, Japan) (223). DMB’s are a primary fibroblast culture prepared from human 
skin (kindly developed and donated by Sheena Jones in the laboratory of Dr D. Marais, University of 
Cape Town, South Africa) and EPC-2 –hTERT (EPC-2) (obtained as gift from Prof A. Rustgi, 
University of Pennsylvania, Philadelphia, USA.) are derived from squamous epithelial cells isolated 
from the morphologically normal proximal oesophagus of a 55 year old male who underwent an 
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oesophagectomy for Barret’s oesophagus. The cell line was immortalized with human telomerase 
(224). 
WHCO1, KYSE 30, KYSE 450 and DMB cells were cultured and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco-BRL, USA) containing 10% heat-inactivated foetal bovine serum 
(FBS) (Gibco-BRL, USA), 100 units penicillin and 100µg/ml streptomycin. EPC-2 cells were grown 
in Keratinocyte Serum Free Medium (KSFM) (Gibco-BRL, USA) supplemented with 50µg/ml bovine 
pituitary extract (Gibco-BRL, USA), 1ng/ml epidermal growth factor (Gibco-BRL, USA), 100 units 
penicillin and 100µg/ml streptomycin. All cell lines were incubated at 37ºC with 5% CO2
 
 humidity. 
On reaching confluency, the cells were rinsed and then harvested with 0.05% trypsin in PBS 
containing 10 mM EDTA, by incubation at 37ºC for 3-5 minutes. In the case of WHCO1 cells, 
trypsinisation was inhibited with the addition of an equal amount DMEM containing 10% FBS.  In the 
case of the EPC-2 cells, trypsinisation was inhibited by the addition of 0.25ng/ml Soya bean trypsin 
inhibitor (Sigma, USA). The cells were pelleted by brief centrifugation at 1000 rpm for 5 min, re-
suspended in their respective media and split at a ratio of 1:5. 
4.2.2 Growth assays 
Cells were seeded at 1500 cells per well, in quadruplicate, in 7 separate 96- well dishes.  After each 
day, 10µl MTT (Sigma, USA) reagent was added to appropriate wells. Subsequently, 100µl 
solubilization reagent (10% w/v SDS, 0.01M HCl) was added after 4hrs incubation with MTT, at 37ºC 
with 5% CO2 humidity. Cells were allowed to solubilize overnight at 37ºC with 5% CO2 humidity. 
Absorbance was read at 595nm using a Biotek EL800 96-well plate reader.  This process was 
repeated over seven days. Doubling time was calculated by plating an exponential growth curve on 
Graphpad Prism version 4.03 (Graphpad Software ©) 
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4.2.3 Cell counting assays 
Cells were seeded at 5X104 in a 6-well dish (35 mm plate), in triplicate. The cells were allowed to 
settle overnight and subsequently treated with 0, 0.5, 5, 10, 50 and 100mM DCA (Sigma, USA) for 
48 hrs. Both media and cells were collected and the amount of cells was counted, using trypan blue 
in order to calculate cell viability and the concentration at which 50% cell death occurs (EC50
Similarly, 2X10
). These 
experiments were performed in triplicate. 
4
4.2.4 Cell cycle analysis 
 cells were seeded in a 24-well dish, in triplicate. The cells were allowed to settle 
overnight and subsequently treated with 0, 10, 50 and 100mM DCA for 0, 12, 24 and 48 hours. Cells 
were counted, using trypan blue, at each time point in order to determine the time at which DCA 
causes cell death at various concentrations. 
Cells were seeded at 0.5X106 per 60 mm dish and allowed to settle overnight. WHCO1 were treated 
with 0 and 10 mM DCA for 48 hrs, whilst KYSE 450’s were treated with 0 and 50 mM DCA for 48 
hours. The cells were harvested using 0.05% trypsin and fixed in ice-cold 70% ethanol. Cells were 
stored at -20°C until further use. For cell cycle analysis, 0.8X106 cells were washed in a phospho-
citrate buffer and to ensure that only DNA stained with propidium iodide, cells were treated with 
RNase A at a final concentration of 50 µg/ml. Cells were then stained for 20 min with a staining 
solution and subjected to flow cytometry on the BD FACSCaliburTM flow cytometer system (BD 
Biosciences, USA). Cell cycle analysis was performed using ModFit
4.2.5 Apoptosis assays (Caspase 3/7 activity) 
 LT™ Software program (Verity 
Software House, USA). 
Cells were seeded at 5000 cells per well in a 96-well plates and allowed to settle overnight. Cells 
were treated with 0, 20, 50 and 100 mM DCA for 6, 12, 24 and 48 hours. Each treatment was 
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performed in quadruplicate. Cells treated with 5µg/ml Doxyrubicin, for the indicated times, were used 
as a positive control. Apoptosis assays were performed using the commercially available Caspase-
Glo ® assay (Promega, USA), according to manufacturers’ instructions, with the following 
modifications. An amount of 60µl of Caspase-Glo ® reagent was added to cells with 60µl media and 
allowed to incubate at room temperature for 30 minutes. Thereafter, 100µl were transferred to an 
opaque plate and allowed to stand at room temperature for a further 30 minutes. Luminescent 
readings were performed using the Glomax 96-plate luminometer (Promega, USA). 
4.2.6 Western Blot analysis (PARP cleavage) 
Cells were seeded at 1X106
4.2.7 Necrosis assay 
 per 60mm dish and allowed to settle overnight. The cells were then 
treated with 0, 10 and 20 mM DCA for 48 hours. Cells treated with 5 µM Doxorubicin for 48 hrs 
served as a positive control for the induction of apoptosis. Protein was prepared by the addition of a 
lysis buffer containing a cocktail of protease inhibitors (cOmplete, Roche) as well as phosphatase 
inhibitors (1M NaF and 0.1 M PMSF). Protein was then subjected to a 10 % SDS-PAGE and 
transferred to nitrocellulose membrane (GE Healthcare, UK). Membranes were blocked with 7% milk 
in TBST for 1 hour at room temperature, and primary antibody (1/1000 dilution in 5% milk for PARP) 
[Santa Cruz, USA], overnight at 4°C, both whilst shaking. Membranes were subsequently shaken at 
room temperature for 1 hour in secondary antibody (anti-rabbit: 1/5000 dilution in 5% milk in TBST) 
[Bio-rad, UK] and detected using SuperSignal ® (Pierce, USA). Images were converted to black and 
white in Microsoft Powerpoint ©. 
Cells were seeded at 1X105 per well (in triplicate) in a 96-well dish an allowed to settle overnight. 
Cells were then treated with 0 and 100mM DCA for 12 hours. In order to determine whether cell 
death involved necrosis, the Cytotox ONE assay was used as per manufacturer’s instructions, with 
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the following modifications. An amount of 60µl of media from each well was transferred to an opaque 
96-well dish and allowed to equilibrate to room temperature. An equivalent amount of Cytotox 
reagent was added to each well for 10 minutes. The reaction was then stopped by the addition of 
30µl stop solution. Cells treated with lysis buffer (provided by the manufacturer) were used as a 
positive control.  The plates were kept in the dark and read immediately by exciting the reagent at 
560nm and recording fluorescence emission at 590 nm on the Carey Eclipse Fluorescence 
spectrometer (Varian Inc, UK)  using slit widths of 10 nm. 
4.2.8 PDH and lactate assays 
Cells were seeded at 0.5X106 
PDH activity was determined as previously described (225), with a few modifications. Briefly, total 
cell activity was measured in triplicate, using [1-
in 35 mm dishes, in triplicate. The cells were allowed to settle 
overnight and subsequently treated with up to 10 mM DCA for 48 hrs. Concentration of lactate was 
determined by removing a 300 µl aliquot of media from each dish and placing on on ice. The media 
aliquot was centrifuged at 1000 rpm for 5 min at 4°C, to pellet any cell debris. The supernatant was 
subsequently placed back on ice and lactate concentration was determined via the Beckman 
Synchron CX9 Clinical System (Beckman Coulter, USA) at Chemical Pathology, National Health 
Laboratory Services, Red Cross Hospital in Cape Town.  
14C]pyruvate (PerkinElmer Life Science Products, 
Boston,MA, U.S.A.) as a substrate, after maximal activation of PDK by treatment of the cells for 15 
min with 5 mM DCA before PDK extraction. The cells were pre-incubated in 0.5 mM CaCl2 and 10 
mM MgCl2 for 10 min at 37°C as previously described (226). Citrate synthase was determined as 
previously described (227). Protein concentration was determined according to the method of 
Bradford, with BSA as the standard (228). 
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Lactate levels and PDH activity was corrected for cell number by using the concentration of protein 
for each dish. 
4.2.9 Statistical evaluations 
For all data comparisons the statistical significance of the differences was determined by the two-
tailed Student’s t-test. Statistical analysis was performed in either Microsoft Excel © or Graphpad 
prism version 5 Software (Graphpad software, San Diego, USA). A p-value of <0.05 was considered 
statistically significant.  
 
 
 
 
 
 
 
 
 
 
4.3 Results 
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4.3.1 Oesophageal cell lines display various levels of sensitivity to DCA treatment 
We investigated various methods to determine the sensitivity of the cell lines to DCA treatment. DCA 
interfered with the MTT reagent resulting in increased absorbance values, unrelated to cell number. 
Although the crystal violet assay displayed the expected decrease in cell viability in response to 
treatment with DCA, the high levels of background observed using this assay, led to the use of cell 
counting assays via trypan blue staining as the method of choice to determine cell viability.  
Table 4.1 outlines the average EC50 for DCA in each cell line calculated from three independent 
experiments. WHCO1 was the most sensitive to DCA with an EC50
Table 4.1: Calculated EC
 of 9mM (CI 8.98-9.03) followed 
by DMB with 11.72 mM (CI 11.42-12.03), EPC-2 with 15.96 mM (CI 15.92-15.99), KYSE 30 with 
32.7mM (CI 32.37-33.05) and KYSE 450 with 41.43 mM (CI 41.02-41.85).   
50
 
’s for DCA and corresponding 95% CI for the panel of cell lines tested. 
 
 
 
 
.  
The morphological appearance of the cells, in response to DCA treatment, corresponded to the EC50 
for DCA. Although the number of fields of view were not documented, the images (Fig 4.2 -4.6) best 
illustrate that at concentrations below the EC50, cells appeared normal whereas abnormal cell 
morphology (rounded cells) were present at DCA concentrations greater than EC50
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Cells treated with DCA displayed a combination of morphological changes including increase in cell 
size, membrane blebbing and in some cases an increased number of vacuoles.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Phase-contrast images of WHCO1 cells treated with (a) 0, (b) 10, (c) 50 and (d) 100 mM 
of DCA for 48hrs. Magnification: 400X 
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Figure 4.3: Phase-contrast images of KYSE 30 cells treated with (a) 0, (b) 10, (c) 50 and (d) 100 
mM of DCA for 48hrs. Magnification : 400X 
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Figure 4.4: Phase-contrast images of KYSE 450 cells treated with (a) 0, (b) 10, (c) 50 and (d) 100 
mM of DCA for 48hrs. Magnification : 400X 
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Figure 4.5: Phase-contrast images of EPC-2 cells treated with (a) 0, (b) 10, (c) 50 and (d) 100 mM 
of DCA for 48hrs. Magnification : 400X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Phase-contrast images of DMB cells treated with (a) 0, (b) 10, (c) 50 and (d) 100 mM of 
DCA for 48hrs. Magnification : 400X 
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Generally the panel of cell lines were not sensitive to DCA as is highlighted by the observation that 
high doses were required for cell death to occur. The panel of cell lines used in this study displayed 
EC50
Despite the high doses of DCA required for cell death to occur in the panel of cell lines used here, we 
investigated whether the mode of cell death was similar to that previously reported.  We selected the 
cell line most sensitive to DCA treatment (WHCO1) and the one least sensitive to DCA treatment 
(Kyse 450) for further investigations. 
 values for DCA that were 10 to 50-fold higher than those used in non-small-lung cancer, 
glioblastoma and breast cancer cell lines (139). It should be noted that the cell lines used in this 
study displayed sensitivities to DCA, similar to those reported for endometrial cancer cell lines (218). 
4.3.2 Time-course of cell death 
Both WHCO1 and Kyse 450 cells display approximately 50% decrease in cell number after 48hrs 
treatment with DCA at concentrations close to their calculated EC50 - 10mM for WHCO1 (Fig. 4.7a) 
and 50mM for KYSE 450 (Fig. 4.7b).  However, when using a concentration that is more than double 
their calculated EC50
 
, both cell lines show an increase in cell death as early as 12 hours post-
treatment with DCA; 50 and 100mM in WHCO1 (Fig. 4.7a) and 100mM in KYSE 450 (Fig. 4.7b), 
respectively. 
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Figure 4.7: Time-course of DCA treatment for (a) WHCO1 and (b) KYSE 450 cells. Cells were 
counted at 0, 12, 24 and 48 hours treatment with 0, 10, 50 and 100 mM DCA. All data points were 
done in triplicate and error bars represent standard deviation. 
 
Since DCA caused inhibition of cell proliferation after 48 hours, a period of 48 hours treatment with 
DCA was subsequently used in all experiments and in the case where the period of DCA treatment 
was shortened, DCA concentration was adjusted accordingly.  
Considering the effects of DCA on cell proliferation, we proceeded to determine the impact of DCA 
on the cell cycle profile of treated cells. 
 
4.3.3 Effects of DCA treatment on the cell cycle profile of OSCC cell lines 
Since the time-course data showed that cell death occurred after 48 hours with 10mM and 50 mM 
DCA treatment, for WHCO1 and Kyse 450 cells, respectively, these were the concentrations used for 
cell cycle analysis.  
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Figure 4.8: Cell cycle analysis of WHCO1 and KYSE 450 cells: (a) Graphical representation of 
average cell cycle profile of WHCO1 displaying no significant changes in cell cycle profile after 
treatment with DCA (b) Cell cycle profile of untreated WHCO1 (c) Cell cycle profile of WHCO1 
treated with 10mM DCA for 48 hrs. (d) Graphical representation of average cell cycle profile of KYSE 
450 where * indicates a significant S-phase arrest (p< 0.05) (e) Cell cycle profile of untreated KYSE 
450 (f) Cell cycle profile of KYSE 450 treated with 50mM DCA for 48 hrs. Data points [in (a) and (d)] 
were done in triplicate and error bars represent standard error from three independent experiments. 
 
Interestingly, both WHCO1 and Kyse 450 cells displayed an increase in S-phase arrest in response 
to DCA treatment; however, this S-phase arrest was only significant in Kyse 450 cells (Fig 4.8). To 
our knowledge, this is the first time that an S-phase arrest, in response to DCA treatment, has been 
observed. Previous studies observed no change in cell cycle profile in response to DCA treatment 
(218,229).  
The S-phase arrest observed in Kyse 450 cells compared to WHCO1 cells could be due to a faster 
doubling time in Kyse 450 cells compared to WHCO1 cells, since this could allow more cells to 
accumulate in the S-phase. However, further investigation revealed no difference in doubling time 
between WHCO1 and Kyse 450 cell lines (Fig. 4.9). 
 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
  107 
                         
        
0 1 2 3 4 5 6 7
0.00
0.25
0.50
0.75
1.00
WHCO1
KYSE450
Days
O
D
@
59
5n
m
 
Figure 4.9: Growth curve for WHCO1 (in red) and KYSE 450 (in black), where the doubling time for 
WHCO1 is 1.646 days and KYSE 450 is 1.659 days. All data points were done in triplicate and error 
bars represent standard deviation. 
 
Although, a significant S-phase arrest was only observed in KYSE 450 cells and not in WHCO1 
cells, cell death occurred in both cell lines when treated with DCA. The method of cell death was 
further investigated. 
4.3.4 Apoptosis or necrosis? 
Firstly, based on the morphological observation of membrane blebbing in some cells treated with 
DCA, we set out to determine whether apoptosis was induced in response to DCA treatment. PARP 
cleavage was first used to determine whether apoptosis was occurring post-treatment with DCA (Fig. 
4.10). Although no PARP cleavage was observed, an alternative method was used to confirm the 
lack of apoptosis. Caspase assays, using a luminogenic substrate, confirmed that no apoptosis was 
observed in either WHCO1 or K450 cells in response to DCA treatment, in comparison to the 
positive control (Fig. 4.11). Unexpectedly, a dose-dependant decrease in caspase activity was 
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observed in cells treated with DCA. A 77% decrease in caspase activity was observed in response to 
20mM DCA treatment for 12 hours for both WHCO1 and Kyse 450 cells, in comparison to the 82% 
and 75% increase in caspase activity for WHCO1 and Kyse 450 cells, respectively, in response to 
doxorubicin treatment (where p<0.005). A more than 90% decrease in caspase activity was 
observed, for both WHCO1 and Kyse 450 cells, in response to 100mM DCA for 12 hours (where 
p<0.0005). The significant error observed in the positive control for WHCO1 is because of one 
particular well, which displayed decreased caspase activity due to possible pipetting error. All other 
data display marginally small error. Furthermore, this decrease in caspase activity was observed as 
early as 6 hours and as late as 48 hours post-treatment with DCA, thereby corroborating the PARP 
cleavage data. In summary, no measurable increase in apoptosis was observed on both WHCO1 
and Kyse 450 cells treated with DCA, despite using two different approaches.  
 
 
 
Figure 4.10: PARP cleavage assay for WHCO1 and KYSE 450 cells. PARP cleavage was 
determined after 48 hours with increasing concentrations of DCA, as indicated. Cells treated with 
5µM doxorubicin for 48 hours were used as a positive control (+). 
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Figure 4.11: Caspase activity assay in WHCO1 and KYSE 450 cells. Caspase 3/7 activity was 
determined after 12 hours after treatment with increasing concentrations of DCA in (a) WHCO1 and 
(b) Kyse 450 cells, as indicated. Cells treated with 5µM doxorubicin for 48 hours were used as a 
positive control (+). All data points were done in quadruplicate and error bars represent standard 
deviation. The decrease, and or increase, in caspase 3/7 activity observed (in comparison to 0 mM) 
are all statistically significant (where * indicates p<0.00005 and ** indicates p<0.005 and *** 
indicates p<0.05) 
 
Since these results suggested that DCA-treated cells were not dying via apoptosis, necrosis was 
investigated as a possible mode of cell death. The necrosis assay is a fluorescent measure of the 
release of lactate dehydrogenase (LDH) from cells with a damaged membrane. The half-life of LDH 
that has been released from cells into the surrounding medium is approximately 9 hours. When the 
assay was performed for longer than 12 hours treatment with DCA, erratic results were obtained. 
Due to the nature of the assay, cells could only be treated for 12 hours. Since our previous time-
course data (Fig. 4.7) indicated that 100 mM DCA treatment for 12 hours resulted in cell death for 
both WHCO1 and Kyse 450 cells, this concentration of DCA was selected to determine whether 
necrosis played a role.  
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Figure 4.12: Necrosis assay after 12 hrs with 0 and 100mM DCA treatment for: (a) WHCO1 and (b) 
KYSE 450 cells. The difference between treated and untreated for both cell lines is significant (where 
P<0.05). All data points were done in triplicate and error bars represent standard deviation. 
 
We observed a significant increase in necrosis in both WHCO1 and Kyse 450 cells in response to 
DCA treatment (Fig. 4. 12). The difference in necrosis observed in the absence of DCA could reflect 
the status of the cells during the experiment (Fig. 4.12). Although every effort was taken to ensure 
constant conditions for both cell lines, Kye 450’s were possibly more stressed in this particular 
experiment, prior to treating with DCA. This does not deter from the fact that both cell lines display a 
significant amount of necrosis is response to DCA treatment. 
 
 
 
4.3.5 DCA does not affect PDH activity and lactate levels in OSCC cell lines 
The mode of action previously described for DCA, as reported for glioblastoma cells, involves the 
inhibition of PDK by DCA; allowing an increase in PDH activity followed by elevated mitochondrial 
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activity (Fig. 4.1). We would predict that this would be associated with decreased production of 
lactate (230). However, even though WHCO1 was shown to be the most sensitive cell line to DCA 
treatment in our panel of cell lines, no difference in PDH activity and an increase in lactate levels 
were observed in cells treated with DCA (data not shown). 
Furthermore, no significant change in PDH activity and lactate levels were observed in any of the cell 
lines treated with DCA (data not shown). The lack of increased PDH activity and decreased lactate 
production after treatment with DCA suggests that DCA is not inducing cell death in oesophageal 
cancer cell lines by the same processes reported by Bonnet et al for glioblastoma cell lines.  
The evidence presented here suggests that DCA causes cell death in our panel of cell lines, via 
necrosis and that the glycolytic pathway does not seem to be targeted. 
 
 
 
 
 
 
4.4 Discussion 
The finding that tumor cells, unlike their normal counterparts, primarily depend on glycolysis 
instead of  mitochondrial oxidative phosphorylation as a source of glucose derived energy, 
despite the availability of oxygen, is known as the "Warburg effect" (131). This property of cancer 
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cells has been exploited in a clinical setting, in the form of positron-emission (PET) scanning, 
allowing earlier detection of tumours. PET scanning takes advantage of the increased uptake of 
glucose of tumour cells, to image tumors in patients, via the use of labelled glucose tracers 
(231). However, the dependence of cancer cells on glycolysis, and reduced mitochondrial 
metabolism also presents as an opportunity for chemotherapeutic targeting. One such 
chemotherapeutic agent that has shown promise in this field is DCA. A recent study by Bonnet 
et al (139) suggested that treatment of cancer cells with DCA could specifically induce 
apoptosis in cancer cells, leaving normal cells unaffected.  The premise of this study is based on 
the observation that DCA inhibits the activity of PDK, thus increasing the flux of pyruvate into 
mitochondria, shunting glucose metabolism from aerobic glycolysis to complete glucose 
oxidation in mitochondria, thus exposing cancer cells to pro-apoptotic factors generated in 
functioning mitochondria.  Our observation (in Chapter 2) that oesophageal cancer cells also 
display elevated levels of glycolytic pathway enzymes, suggested that oesophageal cancer cells 
may also be responsive to DCA treatment in this way.  If this were the case, it could potentially 
alter the face of oesophageal cancer chemotherapy, and in this context, certainly warranted 
further investigation. 
However, the results in this chapter indicate that the panel of oesophageal cancer cell lines 
investigated here, displayed lower sensitivities to DCA treatment than originally reported by 
Bonnet et al for glioblastoma and breast cancer cells and Wong et al for endometrial cancer cell 
lines (139,218).  In the present study, DCA treatment induced cell death in a panel of 
oesophageal cancer cells with an EC50 that ranged from 9 – 40 mM.  The cell proliferation 
assays were carried out by counting cells (using trypan blue), rather than MTT assays, since 
DCA interfered with the MTT reagent.  The experiments reported here were repeated at least 
three times for each cell line, suggesting that the results obtained were reproducible, and 
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multiple batches of DCA were tested, to exclude the possibility that the apparent resistance of 
cells was due to the quality of the DCA tested.  It should be recognised that the Bonnet et al 
article does not specifically report DCA EC50
DCA treatment failed to induce apoptosis in any of the oesophageal cancer cell lines studied 
here, (using two methods to assess apoptosis), unlike the reports for breast cancer, 
glioblastoma, non-small cell lung cancer (139) and endometrial cancer cells (218), where 
induction of apoptosis was readily observed.  Instead, the decrease in cell number observed in 
oesophageal cancer cell lines in response to DCA treatment was due to necrotic processes, and 
not apoptosis.  Furthermore, direct measurement of PDH activity and lactate levels in DCA 
treated oesophageal cancer cell lines indicated that DCA did not have the anticipated effect on 
these glycolytic pathway components.  Given the observations reported by Bonnet et al, it was 
expected that DCA treatment of oesophageal cancer cell lines would result in increased levels of 
PDH activity, and decreased levels of lactate, reflecting the shift to complete oxidation of glucose 
 values for any of the cell lines examined, which 
makes it rather difficult to compare the sensitivities of the cell lines reported.  Instead, Bonnet et 
al comments on the substantial alterations in mitochondrial membrane potentials observed at 
0.5mM DCA, indicating that apoptosis was induced at low DCA levels.  Although the recent 
article by Wong at al (218) that explored the sensitivity of a panel of endometrial cancer cell 
lines to DCA, suggested that DCA sensitized endometrial cells to apoptosis, a careful evaluation 
of the cell growth data is less convincing.  In that study 10 mM DCA failed to decrease cell 
growth in 3 of the 7 cell lines examined, and only reduced cell growth by 10 – 20% in 3 of the 
other cell lines.  Only 1 of 7 cell lines displayed a 50 – 60% decrease in cell number after 
treatment with 10 mM DCA.  The effect of DCA on growth of oesophageal cancer cells observed 
in the present study, is very similar to the results reported by Wong et al for endometrial cancer 
cell lines.   
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in mitochondria.  However, 10 mM DCA had no effect on PDH activity in WHCO1 cells, even 
though these cells were the most sensitive to DCA, with an EC50
In this study we used EPC-2 cells (primary human oesophageal epithelial cells immortalised 
with hTERT) and DMB cells (primary human fibroblasts) as models of “normal” cells, so that the 
effect of DCA can be compared in cancer and normal cells.  Considering that our results show 
that EPC-2 and DMB cells display EC
 of 9 mM.  In addition, 
treatment of WHCO1 cells with 10 mM DCA did not decrease lactate levels, suggesting that 
glucose was not shunted for complete mitochondrial oxidation.  These results are consistent with 
the lack of apoptosis observed in oesophageal cancer cells in response to DCA treatment. 
50
Furthermore, the concentration range required for cell death to occur in our panel of cell lines was 
more that 10-fold the concentrations required for cell death to occur in other cell lines of the breast, 
lung. endometrial and prostate cancer origin (139,218,229). Interestingly, DCA treatment of prostate 
cancer cell lines resulted in an increased sensitivity of these cells to radiation therapy (229), 
suggesting that DCA may have some utility in combination therapy. Although it was reported that 
DCA has low toxicity in animals, the extrapolation of its effects in humans is problematic (232). The 
 values similar to that observed for the oesophageal 
cancer cells lines, we would suggest that DCA was unable to selectively target oesophageal 
cancer cell lines for destruction, above normal cells.  We cannot exclude the possibility that the 
DCA treatment was unable to selectively target oesophageal cancer cells because the “normal 
cells” that we used here was inappropriate for this comparison.  Perhaps a more appropriate 
“normal” cell model would have displayed much more resistance to DCA treatment than 
observed here.  However, it is also equally possible that not all cancer cells respond to DCA 
treatment by activating apoptosis.  This is highlighted by the observation that 2 of the 7 
endometrial cancer cell lines tested for sensitivity to DCA were very resistant to the apoptosis-
inducing effects of DCA (218).   Un
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results from our study together with the concerns of DCA’s irreparable neurotoxic effects, identified 
from a randomized clinical trial of the effects of DCA (233), highlights that the use of DCA as a 
potential cancer therapeutic agent is still in its infancy and requires meticulous pre-clinical and 
clinical evaluation (220,234). 
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5 Conclusion  
OSCC occurs at a high frequency in SA and is associated with a high mortality rate, making a South 
African cohort of OSCC patients a good model to study the development of the disease.  Few studies 
have reported on molecular events leading to the development on OSCC in a South African cohort 
(101,235). Diagnosing the disease earlier or identifying better therapeutic targets remain a challenge.  
The aim of this study was to identify potential diagnostic markers and/or therapeutic targets using 
proteomic approaches. The objectives of both proteomic approaches was to identify altered protein 
expression in tumour compared to normal cells, validate altered protein expression and explore the 
potential of altered protein levels as markers for OSCC or as targets for therapeutic intervention.  
Two proteomic techniques were applied to investigate the potential of membrane or membrane 
associated proteins as targets for therapy or for earlier diagnosis of the disease. 
Although the application of 2D-DIGE to proteins from tumour and normal tissue identified a 
number of membrane and membrane-associated proteins, only Annexin 2, PK2 and GAPDH 
were subsequently validated and explored further. 
We cannot conclusively state that the increase in annexin 2 expression was not related to the 
survival status of patients with OSCC, as the statistical power of the study is not significant. 
Unfortunately, due to limited patient sample, an IHC study of a larger cohort was not possible.  
Nevertheless, the increased levels of annexin 2 in OSCC tissue compared normal tissue, 
renders it as a potential therapeutic target. Future studies should include further molecular 
investigation as to contribution of annexin 2 in the development of OSCC, to determine its value 
as a potential therapeutic target in OSCC.  
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The increased level of glycolytic enzymes (PK2 and GAPDH) in tumour tissue was explored as a 
target for therapeutic intervention in OSCC. According to previous reports, OSCC was expected 
to be an ideal candidate for DCA treatment, based on its increased levels of glycolytic enzymes 
compared to normal tissue. Bonnet et al (139) neglected to report dose response curves (to 
calculate EC50
 
) for treatment with DCA, however, their murine models convincingly showed a 
reduction in tumour size post-treatment with DCA.  Our model revealed that the concentrations 
of DCA required for cell death to occur was 10-fold more than concentrations required to cause 
cell death in other cancers (139,218). Furthermore, DCA caused cell death via a different 
pathway than previously reported. The significance of this study, based on these results, is that 
DCA will not be effective in the therapeutic intervention of patients with OSCC. However, further 
investigations, perhaps using in vivo mouse models (as Bonnet et al showed (139)) would be 
able to determine the potential of DCA as a therapeutic strategy in OSCC. 
REQUA identified one glycosylated membrane protein, namely, CD98 hc. One of the significant 
findings of this study is that it marks CD98 hc as a good candidate as an early diagnostic marker 
and potential therapeutic target in OSCC. CD98 hc’s potential as an early diagnostic marker and 
a potential therapeutic target is currently being explored in other cancers (215,216) and we 
recommend, based on our results, that OSCC be included in these trials. Furthermore, future 
studies should include an immunohistochemical study of CD98 hc in a larger cohort of OSCC 
patient (and corresponding normal) material, to determine CD98 hc’s potential as a marker of 
survival, as was performed with annexin 2 in this study. 
In summary this study achieved all its objectives, as we identified a number of membrane and 
membrane-associated proteins that displayed altered protein patterns in tumour cells compared 
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to normal cells. The proteins’ of interest expression levels were validated. Finally, the potential of 
some of these proteins were explored further. 
Appendix A:  
Chapter 2 
HEPES Buffer (ph 7.4):10 mM HEPES and 1 mM EDTA 
Plasma membrane preparation 
Cocktail of protease inhibitors (cOmplete, Roche):  
Stock solution : 1 tablet dissolved in 2ml dist water and separated into 100µl aliquots, results 
in a 10X stock solution, which is diluted to 1X with HEPES buffer, for every 200µl used 20µl 
of stock was included e.g. 180µl buffer plus 20µl stock  
phenylmethanesulphonylfluoride or phenylmethylsulphonyl fluoride (PMSF) : Stock solution = 50 
mM, final concentration in homogenate should be 1mM therefore need a 1/50 dilution from stock. 
E.g. if final volume is 3ml homogenate, include 60µl stock solution.    
CyDyes (NHS-Cy2, -Cy3, -Cy5): from lyophilized powder (stored at -20ºC), reconstitute to 1 mM 
stock by dissolving in the appropriate volume of anhydrous DMF. Keep stock solutions in dark at -
20ºC. Stable for up to 4 months. 
2D-DIGE and CCB staining 
Lysis buffer (pH 8.3): 8 M urea, 2 M thiourea, 4% (w/v) CHAPS, 0.5% NP-40 (w/v), 10 mM Tris-HCl 
pH 8.3. To make 100 mL, dissolve 48 g of urea and 15.2 g of thiourea in 50 mL of distilled H2O. Add 
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4 g CHAPS, 0.5 g NP-40 and 0.67 mL of 1.5 M Tris pH 8.8 solution. 40% (w/v) CHAPS: For 50 mL, 
dissolve 20 g CHAPS in H2
10% (w/v) NP-40: For 50 mL, dilute 5 g of 100% NP-40 in H
O and adjust to 50 mL.  
2
L-lysine solution: 10 mM L-lysine in H
O and adjust to 50 mL.  
2O. Dissolve 9.1 mg in 5 mL distilled H2
DTT solution: 1.3 M DTT in H
O.  
2O. To make 10 mL, dissolve 2 g DTT in distilled H2
Ampholines/Pharmalyte mix: Mix equal volumes of ampholines (pH 3.5-10) and Pharmalyte (pH 3-
10). Store at 4ºC. These broad pH range IPG buffers can be replaced with narrow range buffers 
depending on the 1st dimension pH range. 
O and complete to 
10 mL. Aliquot and store at -20ºC.  
Bromophenol blue: 0.2% (w/v) bromophenol blue in H2O. To make 10 mL, weigh 20 mg 
bromophenol blue and complete to 10 mL with distilled H2
Bind Saline solution: For twelve 24 cm x 20 cm plates, mix 16 L of Plus One Bind Saline, 400 L 
glacial acetic acid, 16 mL ethanol and 3.6 mL distilled H
O. Filter and store at room temperature.  
2
Equilibration buffer: 6 M urea, 30% (v/v) glycerol, 50 mM Tris-HCl pH 6.8, 2% (w/v) SDS. To make 
200 mL, dissolve 72 g urea in 100 mL distilled H
O. 
2O. Add 60 mL of 100% glycerol, 10 mL of 1 M Tris 
pH 6.8 solution and 4 g SDS. Dissolve all powders and adjust volume to 200 mL with distilled H2
Agarose overlay: 0.5% (w/v) low-melting point agarose in 1x SDS electrophoresis buffer. To make 
200 mL, melt 1 g of agarose in 200 mL of 1x SDS electrophoresis buffer in a microwave on low heat. 
Add bromophenol blue solution to give a pale blue colour 
O. 
Aliquot and store at -20ºC. 
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Fixing solution: 35% (v/v) methanol, 7.5% (v/v) acetic acid in distilled H2
Colloidal CBB fixing solution: For colloidal Coomassie brilliant blue staining, fix gels in 35% (v/v) 
ethanol, 2% (v/v) phosphoric acid in distilled H
O. 
2
Colloidal CBB staining solution: 34% (v/v) methanol, 17% (w/v) ammonium sulphate, 3% (v/v) 
phosphoric acid in distilled H
O. 
2
Calmix Standards 
 
Peptide MW Final Conc 
pmol 
Stock Conc/L Stock Vol/L 
Bradykinin   757.3 0.500 576 pmol     8.68 (1/10) 
Angiotensin I 1296.6 0.500 650 pmol     7.69 (1/10) 
Angiotensin II 1046.5 0.500 450 pmol   11.10 (1/10) 
Bombesin 1619.8 1.00 1     nmol   10.00 (1/10) 
Renin 1758.9 1.00 230 pmol     4.35 
ACTH (1-17) 2093.08 1.00 132 pmol     7.58 
ACTH 918-39) 2465.19 2.00 200 pmol   58.80 
Insulin B Chain 3494.65 3.00 184 pmol   16.35 
    
Total vol 
 
134.55 
 
O. 
 
Magnification was represented as magnification of objective X 10 (magnification of ocular)  
IHC images 
Chapter 3 
Trypsin-EDTA: 0.05 % (w/v) trypsin, 0.8 % (w/v) NaCl, 0.15% (w/v) Na
Cell culture 
2HPO4.2H2O, 0.02% (w/v) 
KCl, 0.02% (w/v) KH2PO4
PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na
 and 10 mM EDTA (pH 8.0) 
2HPO4.7H2O (pH 7.4) and 1.4 mM KH2PO4 
Un
ive
rsi
ty 
of 
Ca
pe
 T
wn
  121 
Penicillin/streptomycin solution: 5X106
 
 U Penicillin G Sodium (supplied by Highveld Biological) to 5 
ml PBS plus 5 g 214S Streptomycin Sulphate (Highveld Biological) to 15 ml PBS. Combine the two 
and make volume up to 500 ml with PBS. Aliquots of 5 ml volumes are added to each 500 ml 
volume of media. 
 
REQUA, gel electrophoresis and staining 
Labeling/Incubation mix
HEPES saline buffer: 10 mM HEPES and 140 mM NaCl 
 (Table A1) 
UDP[6-3
UDP [U-
H]GaI : (supplied by GE Healthcare as an ammonium salt in 50% aqueous ethanol at a 
specific activity of 5-20 Ci/mmol or 1 mCi/ml) is diluted to 40µCi/ml in the labeling mix. 
14
Galactosyltransferase: (supplied by Sigma: 
C]Gal :(supplied by GE Healthcare as an ammonium salt in an aqueous solution 
containing 2% ethanol at a specific activity of 200mCi/mmol or 25 µCi/ml) is diluted to a 
concentration of 40µCi/ml in the labeling mix  
G5507, obtained from
MnCl: 50mM stock diluted to 5mM in labeling mix 
 bovine milk as a lyophilized 
powder, 3-15 U/mg protein in the presence of adequate α-lactalbumin) is diluted to a final 
concentration of 0.5 U/ml in the labeling mix 
Table A 1: Illustrating guidelines for volumes of labeling mix constituents. **Because 3H is in 50% 
ethanol and cells are sensitive to ethanol (whereas 14C is in an ammonium salt buffer hence more 
compatible with cells), hence at least 50% of the ethanol’s volume needs to be evaporated with 
nitrogen at 4°C. e.g. if you have 4 plates: you require 200µl labeling mix per plate therefore need 
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800ul of total labeling mix. The amounts one will use is therefore 80 ul GT, 80ul MnCl, 40ul 
Radiolabelled galactose and make up to 800ul with 600 ul HeS 
HEPES Saline 
 
       3H** or 14
 
C    Galactosyltransferase 
      MnCl  
(50mM stock) 
   Total volume 
  x-depends on  
amount required    
to make up total 
volume 
100ul/2ml total 
volume     1/10
th
   1/10
 of total volume 
th
       volume 
 of total  x- depends on 
amount required 
 
Homogenisation Buffer (pH 7): 0.25M Sucrose, 2mM EDTA and 10mM HEPES 
Protease inhibitor: 1 cOmplete tablet was dissolved in 5 ml dH2
Percoll: (supplied by Sigma: P1644) diluted to 27% of total volume (Table A2) 
O to make a 10x solution. Aliquots 
were stored at -20°C.  
Table A 2: Illustrating an example of typical volumes in the Percoll ® gradient  
Sucrose Percoll HB PNS 
500ul 5.67 15.33 2ml 
 
80% sucrose: 80% (w/v) in H2
30% Acrylamide: 30% (w/v) acrylamide, 0.8% (w/v) bis-acrylamide and 0.1 g (w/v) SDS 
O 
Stacking Buffer (pH 6.3): 0.5 M Tris, 0.4% (w/v) SDS pH to 8.0  
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Resolving buffer (pH 8.8): 1.5 M Tris and 0.4% (w/v) SDS 
Large format 8% to 15 % gradient SDS-PAGE: Table A3 
Table A 3: Indicating volumes used to make up 8% to 15% gradient gels 
 8% 15% 
H2 17.4 O (ml) 4.8 
Resolving buffer (ml) 9 9 
30% Acrylamide (ml) 9.6 15.6 
 
10X Electrophoresis buffer: 4% (w/v) glycine, 6.32% (w/v) Tris and 1% SDS. Dilute 1 in 10 for 1x 
running buffer 
Coomassie Blue staining solution: 50% (v/v) methanol, 10% (v/v) acetic acid and 0.25% (w/v) 
De-staining solution: 10% (v/v) methanol and 7.5% (v/v) acetic acid 
Magnification was represented as magnification of objective X 10 (magnification of ocular)  
IHC images 
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Patient number
DATE 
DIAGNOSED/regist
ration date SURVstatus Stage Last follow up/death
Survival in 
years
1 4/28/1986 DEAD 2 1/1/2003 16.69041096
2 7/14/1986 DEAD 3 2/27/1994 7.630136986
3 1/19/1989 ALIVE 2 10/13/2006 17.74246575
4 6/29/1989 DEAD 3 7/7/1989 0.021917808
5 7/6/1989 ALIVE 2 11/13/2006 17.36712329
6 8/17/1989 DEAD 3 11/30/2001 12.29589041
7 9/28/1989 ALIVE 2 2/17/2006 16.4
8 1/25/1990 DEAD 3 5/17/1991 1.306849315
9 4/5/1990 DEAD 2 12/23/1990 0.717808219
10 5/17/1990 DEAD 2 12/5/1990 0.553424658
11 6/7/1990 DEAD 3 2/17/1992 1.698630137
12 1/3/1991 DEAD 2 2/11/1991 0.106849315
13 3/28/1991 DEAD 2 6/10/1991 0.202739726
14 5/7/1991 DEAD 3 6/11/1992 1.098630137
15 11/18/1991 DEAD 3 12/14/1991 0.071232877
16 1/23/1992 DEAD 2 11/8/2000 8.8
17 4/16/1992 DEAD 3 8/22/1994 2.350684932
18 5/21/1992 DEAD 2 2/16/1994 1.742465753
19 7/2/1992 DEAD 2 9/25/1995 3.232876712
20 7/16/1992 DEAD 2 8/30/1992 0.123287671
21 8/20/1992 DEAD 3 6/3/1994 1.78630137
22 9/10/1992 DEAD 2 9/29/1992 0.052054795
23 1/14/1993 DEAD 2 1/30/1993 0.043835616
24 1/21/1993 DEAD 3 6/1/1993 0.35890411
25 1/21/1993 DEAD 2 10/28/1996 3.769863014
26 3/4/1993 DEAD 3 3/20/1993 0.043835616
27 3/25/1993 DEAD 3 7/15/1993 0.306849315
28 4/2/1993 DEAD 3 6/26/1993 0.232876712
29 5/25/1993 ALIVE 2 6/30/2006 13.10684932
30 8/20/1993 DEAD 3 9/25/1993 0.098630137
31 2/4/1994 DEAD 3 7/2/1994 0.405479452
32 4/23/1994 DEAD 3 10/5/1994 0.452054795
33 12/4/1994 DEAD 3 12/11/1995 1.019178082
34 1/13/1995 DEAD 1 2/21/1995 0.106849315
35 1/27/1995 ALIVE 2 5/5/2006 11.27671233
36 4/21/1995 DEAD 3 12/9/1996 1.638356164
37 8/4/1995 DEAD 2 9/28/1995 0.150684932
38 8/25/1995 DEAD 3 6/22/1996 0.82739726
39 10/20/1995 DEAD 3 9/2/1996 0.871232877
40 11/3/1995 ALIVE 2 11/6/2006 11.01643836
41 1/19/1996 DEAD 2 1/1/1997 0.953424658
42 1/13/1997 DEAD 2 4/17/2004 7.263013699
43 2/14/1997 DEAD 2 7/19/1998 1.424657534
44 4/11/1997 DEAD 2 6/18/1998 1.18630137
45 9/19/1997 ALIVE 1 11/15/2006 9.161643836
46 11/6/1997 DEAD 2 4/30/1998 0.479452055
47 3/3/1998 DEAD 2 6/6/1999 1.260273973
48 4/17/1998 DEAD 3 8/21/1998 0.345205479
49 5/7/1998 DEAD 3 8/7/1998 0.252054795
50 6/18/1998 DEAD 2 1/1/2004 5.542465753
51 7/7/1998 DEAD 2 10/17/1998 0.279452055
52 12/11/1998 DEAD 2 12/1/2001 2.975342466
53 2000-02-14 DEAD 2 10/3/2000 0.635616438
54 5/22/2000 DEAD 2 7/30/2004 4.191780822
55 3/10/2006 ALIVE 3 8/18/2006 0.44109589
56 10/1/2002 ALIVE 2 6/30/2006 3.747945205
57 8/6/2004 ALIVE 2 7/14/2006 1.936986301
58 12/3/2004 ALIVE 3 10/20/2006 1.879452055
59 11/30/2001 ALIVE 2 10/27/2006 4.909589041  
Table A 4: Status of 59 
patients used in statistical 
evaluations at the time of 
analysis   Note: the 18 
patients used for 
confirmation of protein 
expression were included 
in the 59 patients used. 
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Chapter 4 
DCA: (supplied by Sigma: 34, 779-5) diluted in PBS to desired concentration 
Magnification was represented as magnification of objective X 10 (magnification of ocular)  
Phase contrast images 
MTT: (supplied from sigma: M2128) diluted 5mg/ml in Sterile 1 x PBS solution, pH 7.4 (sterile 
filtered) 
Growth assay 
Solubilisation reagent: 10% SDS in 0.01M HCl, non sterile. 
Staining solution: 0.1 % Triton X100, 2 mM MgCl
Cell cycle 
2, 100 mM NaCl, 0.01 M PIPES buffer and 10 
µg/ml propidium iodide 
Lysis buffer: 150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 10 mM Tris at pH 7.5 and 1% 
(w/v) Na-deoxycholate 
Western blotting 
Protease inhibitor: 1 cOmplete tablet was dissolved in 5 ml dH2
Lysis buffer plus protease and phosphatase inhibitors: 1µM Na
O to make a 10x solution. Aliquots 
were stored at -20°C.  
3VO4, 20 µM NaF and 10% protease 
inhibitor 
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30% Acrylamide: 30% (w/v) acrylamide, 0.8% (w/v) bis-acrylamide and 0.1 g (w/v) SDS 
Stacking Buffer (pH 8): 5.9% (w/v) Tris, 0.4% (w/v) SDS pH to 8.0  
Resolving Buffer (pH 8.9): 36.2% (w/v) Tris and 0.8% (w/v) SDS 
5x Loading Buffer (pH 6.8): 3.5% (w/v) Tris, 60% (v/v) glycine and 5% (w/v) SDS 
Loading Dye: 200 µl 5x loading buffer, 100 µl β-mercaptoethanol, 100 µl saturated, filtered 
bromophenol blue 
10X Electrophoresis buffer: 4% (w/v) glycine, 6.32% (w/v) Tris and 1% SDS. Dilute 1 in 10 for 1x 
running buffer 
10x Transfer Buffer: 14.4% (w/v) glycine and 3.8 % (w/v) Tris 
1x Transfer Buffer: 100 ml 10x transfer buffer, 200 ml isopropanol and 700 ml H2
Coomassie Blue staining solution: 50% (v/v) methanol, 10% (v/v) acetic acid and 0.25% (w/v) 
O 
De-staining solution: 10% (v/v) methanol and 7.5% (v/v) acetic acid 
Ponceau-S stain solution: 0.1% (w/v) Ponceau S and 1% (v/v) glacial acetic acid 
10x Tris buffered saline (pH 7.5): 6.05 % (w/v) Tris, 8.76% (w/v) NaCl 
TBS plus 0.1 % Tween: 100 ml 10x TBS, 900 ml dH2
Fixer (AGFA G333C): Dilute 100 ml stock solution with 400 ml H
O and 1 ml Tween 20 
2
Developer (AGFA G128): Dilute 100 ml stock solution with 400 ml H
O 
2O 
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10x MOPS: 0.4 M MOPS pH 7.0, 0.1 M sodium acetate and 0.01 M EDTA 
RNA gel electrophoresis 
Formaldehyde loading buffer: 5.3% (v/v) saturated bromophenol blue, 6.66% (v/v) glycerol, 10.7% 
(v/v) 10X MOPS, 17.3% (v/v) 12.3M formaldehyde and 47% (v/v) formamide. 
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Appendix B:  
 
 
 
 
 
 
 
 
 
 
 
 
Annexin 2 
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Figure B 1: Mass spectrum for annexin 2. The mass-to-charge ratio (m/z) is on the x-axis and signal 
intensity is represented on the y-axis. MS data was generated as described in materials and 
methods, and internally calibrated using trypsin autolysis peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GP96HSP90B1 
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Figure B 2: Mass spectrum for HSP90B1. The mass-to-charge ratio (m/z) is on the x-axis and signal 
intensity is represented on the y-axis. MS data was generated as described in materials and 
methods, and internally calibrated using trypsin autolysis peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gelsolin
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Figure B 3: Mass spectrum for gelsolin. The mass-to-charge ratio (m/z) is on the x-axis and signal 
intensity is represented on the y-axis. MS data was generated as described in materials and 
methods, and internally calibrated using trypsin autolysis peaks. 
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Figure B 4: Mass spectrum for GAPDH. The mass-to-charge ratio (m/z) is on the x-axis and signal 
intensity is represented on the y-axis. MS data was generated as described in materials and 
methods, and internally calibrated using trypsin autolysis peaks. 
 
 
 
 
 
 
 
 
 
 
 
 
Pyruvate kinase
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Figure B 5: Mass spectrum for pyruvate kinase. The mass-to-charge ratio (m/z) is on the x-axis and 
signal intensity is represented on the y-axis. MS data was generated as described in materials and 
methods, and internally calibrated using trypsin autolysis peaks. 
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